Drugs Made In AMERICA Acquisition Corp I

Drugs Made In AMERICA Acquisition Corp II

Drugs Made In AMERICA Acquisition Corp III

Drugs Made In AMERICA Acquisition Corp IV

PharmAGRI™ Investors LLC

Regional Center BrightGreen LLC

Coming Soon...

PharmAGRI™ CAPITAL PARTNERS CO

Comprehensive Business Plan

Contact Person: Mr. John Stockwell

Email: johnkstockwell@hotmail.com

Confidentiality Statement

This document (the "Business Plan") contains confidential information proprietary to PharmAGRI Capital Partners Co., from now on referred to as the "Company" (the "Company"). This information and related conversations are submitted solely to introduce selected parties to the Company's Business Plan. The Company's disclosure of information contained herein and in related conversations does not constitute authorization for the recipient of the Business Plan to use the information, ideas, or concepts contained herein for any purpose other than the evaluation of the Company or to disclose any information to any other parties. The Company retains ownership of this Business Plan, including any concepts and ideas described herein.

Each recipient of this document agrees to treat the information strictly confidentially. The recipient may not disclose, directly or indirectly, or permit any agent or affiliate to disclose any information contained herein or reproduce this document in whole or part without the Company's prior written consent unless otherwise required by applicable law.

Any party that accepts delivery of this Business Plan, or any other document(s) or verbal communication(s) of confidential information from the Company, agrees to be bound by the terms of this Confidentiality Statement and further agrees to promptly return any such documents and materials to the Company upon request.

Disclaimer Statement

The market analysis and financial projections presented herein represent the Company's best judgment and reasonable assumptions of future events and circumstances; all other information contained herein has been obtained from reliable sources. However, no warranty or representation, expressed or implied, is made as to the accuracy or completeness of any information contained herein, and the same is submitted subject to errors and omissions. No representations or warranties of future company performance or market trends are intended, and such are expressly disclaimed.

Forward-Looking Statements

This information contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, expectations regarding strategic settlements, indemnification outcomes, Nasdaq relisting, capital raises, and the development of sovereign pharmaceutical infrastructure. Words such as “anticipates,” “believes,” “expects,” “intends,” “plans,” “may,” “will,” “should,” and similar expressions are intended to identify forward-looking statements. These statements are based on current assumptions and involve risks and uncertainties that could cause actual results to differ materially. Such risks include, but are not limited to, adverse judicial rulings, regulatory delays, market volatility, reputational harm, and the outcome of ongoing litigation and settlement negotiations. The Company undertakes no obligation to update any forward-looking statements, except as required by law.

Mission Statement

PharmAGRI exists to restore American sovereignty over pharmaceutical and agricultural supply chains by building federally aligned, quota-backed infrastructure that empowers farmers, protects public health, and regenerates capital. We deploy robotics, compliance automation, and strategic capital to transform U.S. farming into a high-value engine for Schedule II-V drug production-anchored by DEA quota, federal procurement, and public governance. Our mission is to displace imports, secure domestic control, and build the sovereign infrastructure bank for food and medicine.



SIMPLE BUSINESS STRATEGY:

“Drugs Made in America”

Lynn Stockwell | CEO and Chairperson

United States Federal Alignment to onshore all plant-based prescription drugs>DEA Quota>Pharm AGRI Capital Partners, Investment in American farm owner-operators infrastructure>contract farmer quota production>deliver biomass to super-pharm pharmaceutical factory> biomass storage>API manufacturing>contracts for procurement of finished drugs>prescription drug manufacturing>delivery to government agencies

= Seed-to-Prescription Drug

Executive Summary:

Federal Rebirth and Sovereign Integration for the Drugs Made in America Platform

Bright Green Corporation's federally authorized facility in Grants, New Mexico marks a historic inflection point in U.S. pharmaceutical infrastructure. As the only DEA-approved site for Schedule I and II drug production at pharmaceutical scale, it anchors the "Drugs Made in America" initiative with full-spectrum compliance—from biomass cultivation and extraction to formulation, packaging, and direct-to-patient delivery. This facility is not a pilot—it is a sovereign manufacturing platform with federal alignment, quota-secured operations, and the capacity to produce controlled substances never legally manufactured on U.S. soil.

Under Lynn Stockwell's litigation-tested leadership, Bright Green has executed a strategic transformation from reputational collapse to sovereign continuity. Through documented governance, indemnification oversight, and federal filings, Stockwell restored procedural integrity and repositioned the company as a federally compliant entity.

The proposed merger with PharmAGRI Capital Partners consolidated assets under a clean corporate structure, unlocking access to a $10 billion investment roadmap and a network of 60 DEA-licensed mega farms to produce pharmaceutical biomass for the API and drug manufacturing of prescription drugs.

Also important for onshoring new CEA food opportunities for the federal school lunch programs. This integration not only neutralized legacy liabilities—it created a vertically integrated platform capable of absorbing federal contracts, institutional capital, and strategic acquisitions.

Bright Green Corporation's New Mexico Facility: A National First in DEA Schedule I–V Production

Bright Green Corporation's high-security facility in Grants, New Mexico stands as the nation's only federally authorized operation capable of producing and manufacturing DEA Schedule I through V controlled substances. This facility serves as the proof of concept for a new pharmaceutical manufacturing paradigm—one rooted in domestic sovereignty, regulatory compliance, and scalable infrastructure.

By securing DEA and New Mexico Board of Pharmacy approvals, Bright Green has positioned itself to lead a new industry: the legal, domestic production of plant-based and synthetic active pharmaceutical ingredients (APIs) across all DEA schedules. This milestone enables the Company to reduce U.S. dependency on imports, support federal drug supply chain initiatives, and anchor the "Drugs Made in America" movement with unmatched operational integrity.

PharmAGRI Capital Partners now serves as the operational and contractual backbone of the platform, executing DEA quota contracts, farm production agreements, and long-term supply arrangements that anchor federal eligibility. Its infrastructure supports DEA-registered and FDA-compliant pharmaceutical inputs, enabling centralized compliance and consistent delivery across all acquisitions.

PharmAGRI has curated a strategic pipeline of planned acquisitions designed to strengthen global market experience, expand revenue channels, and introduce patented plant technologies that accelerate U.S. onshoring efforts.

Bright Green Corporation will relist on Nasdaq in Q4 2025 effectively taking the platform public by leveraging its documented governance history, DEA-authorized infrastructure, and post- Chapter 11 restructuring. The roadmap includes finalizing the reverse stock split, transmitting updated SEC disclosures reflecting the PharmAGRI merger, and certifying compliance with Nasdaq's corporate governance and public float requirements. The integrated entity—anchored by federally aligned production of DEA Schedule I–V substances—will restore shareholder value and meet listing standards through traceable operations, EB-5 job creation metrics, and sovereign pharmaceutical capabilities.

PharmAGRI, now formalized as the sovereign supply engine behind the Drugs Made in America brand, will de-risk the U.S. pharmaceutical supply chain by replacing foreign dependencies with domestic, quota-backed manufacturing. Upon relisting, the platform will be positioned for federal contract readiness and export expansion—leveraging its DEA quota, FDA compliance, and vertically integrated infrastructure to penetrate international markets. If global tariffs persist, the group's legal manufacturing authority and EB-5 alignment offer a unique hedge against geopolitical instability and supply chain disruption.

Drugs Made in America Acquisition Corps I–IV are strategically structured SPACs, each designed to deploy capital toward acquiring FDA-compliant, revenue-generating pharmaceutical companies. DMAA and DMII are already Nasdaq-listed, with additional Corps advancing toward listing and acquisition execution. Lynn Stockwell serves as Sponsor, CEO, and Chairwoman across all four entities, maintaining direct ownership and board control to enforce strategic continuity. Each acquisition is selected for its ability to contribute proprietary technology, regulatory expertise, and scalable manufacturing capacity - transforming each target into a sovereign node within a federally aligned infrastructure.

PharmAGRI Investors LLC anchors upstream operations as the EB-5 Job Creating Enterprise, deploying capital into quota-driven biomass cultivation and permanent job creation. Governed by a sole board authority with full settlement and indemnification oversight, it documents every capital deployment and employment metric for USCIS, carrier review, and investor protection. This structure ensures that sovereign pharmaceutical production is not only federally compliant—it is economically regenerative, legally insulated, and procedurally documented.

Together, Bright Green Corporation, PharmAGRI Capital Partners, PharmAGRI Investors LLC, and the Drugs Made in America Acquisition Corps form a vertically integrated, federally aligned pharmaceutical platform. By anchoring acquisitions in sovereign infrastructure and quota- secured supply chains, the platform offers predictable cash flows, strategic growth through MCA, and durable investor returns. Most importantly, it positions the United States to reclaim control over its pharmaceutical future—legally, transparently, and at scale.

The strategic deployment of Tesla Optimus Gen-3 robotics within PharmAGRI's sovereign pharmaceutical and agricultural infrastructure represents a pivotal advancement in domestic automation. By integrating Tesla's humanoid systems into plant-based pharmaceutical processing, greenhouse cultivation, and sterile logistics environments, this collaboration directly supports federal mandates under DEA, USDA and HHS directives. It enhances operational precision, scalability, and compliance while accelerating the transition to resilient, onshore production systems. This alignment with Executive Orders and national industrial policy reinforces both parties' commitment to restoring pharmaceutical sovereignty and modernizing high-impact sectors.

Operationally, Tesla Optimus Gen-3 offers a uniquely adaptive platform for environments requiring high levels of repeatability, sterility, and energy efficiency. Its modular limb systems, OTA software architecture, and AI-driven task learning make it ideal for deployment across cleanrooms, controlled agriculture zones, and logistics hubs. PharmAGRI's vertically integrated model provides a robust testbed for co-developing robotics certification pathways, modular training programs, and ESG-aligned automation protocols. Together, Tesla and PharmAGRI will pioneer scalable automation that elevates workforce roles, reduces turnover, and ensures compliance with immigration and labor standards—setting a precedent for responsible innovation.

Beyond technical integration, this collaboration reflects a shared vision for socially conscious industrial transformation. By transitioning low-skill roles into high-value, tech-enabled careers, both parties' advance workforce sustainability and economic mobility. Tesla's commitment to retraining initiatives and federal engagement complements PharmAGRI's leadership in restoring reputational and procedural integrity across sovereign platforms.

This Tesla partnership not only accelerates the deployment of intelligent automation but also reinforces the broader mission of building a secure, federally aligned pharmaceutical and agricultural ecosystem—one that can ensure federal compliance and builds a reliable in-house supply chain.

Drugs Made in America, backed by PharmAGRI Capital Partners, is not merely a pharmaceutical initiative—it is a national imperative. By supporting DEA- and FDA-controlled manufacturing to

U.S. soil, this platform eliminates foreign diversion risks, fortifies regulatory integrity, and reclaims America's authority over its most sensitive medical supply chains. No longer will our nation outsource the stewardship of controlled substances to jurisdictions with opaque oversight. The DEA and FDA must be empowered—not bypassed—to enforce the law, protect the public, and ensure that every molecule produced serves only its intended, lawful purpose.

This is pharmaceutical sovereignty in action.

American farmers have the best technologies for controlled substances.

Purpose

The Plan will be used to develop the S1 disclosures for the Securities and Exchange Commission for a NASDAQ listing 4th quarter 2025

In addition, the plan aims to provide USCIS with the information necessary to evaluate the scope and economic impact of PharmAGRI Capital Partners Co. This plan will show the following:

There is sufficient induced job creation to justify a $10B EB-5 Investment.

A significant market opportunity exists when analyzing the current market demands and competitive landscape.

The management team can execute a well-thought-out operational strategy.

The correct capital structure will allow for a long-lasting, profitable business.

Table of Contents

Project Name	PharmAGRI
Job-Creating Entity and Project Company	PharmAGRI Investors LLC Delaware Limited Liability Company
New Commercial Enterprise and Partnership	PharmAGRI Capital Partners Co. Delaware Corporation
Regional Center	Bright Green LLC
Project Description	A sovereign infrastructure initiative integrating advanced production facilities and strategic acquisitions to secure U.S. pharmaceutical and agricultural independence through vertically controlled, federally aligned supply chains.
Location	Amarillo, Texas
Industry Sectors and NAICS Codes	325412 – Pharmaceutical Preparation Manufacturing 111419 – Other Food Crops Grown Under Cover 115112 – Soil Preparation, Planting, and Cultivating 541714 – Research and Development in Biotechnology (except Nanobiotechnology) 236220 – Commercial and Institutional Building Construction 493120 – Refrigerated Warehousing and Storage 561110 – Office Administrative Services
Target Employment Area	Yes
Total Investment	$14 Billion Phase I – $5.5 Billion Phase II – $5.5 Billion Phase III – $3 Billion
Total EB-5 Loan	$10 Billion
Convertible Private Placement White House Accelerator Program	$2 Billion $0
Federal Loan Guarantees	$2 Billion
Total Full-time Jobs Created	100,000+ Jobs
Use of Funds	Facility development, strategic acquisitions, and operational setup to establish a fully integrated pharmaceutical and agricultural supply chain.

The Project

PharmAGRI Capital Partners Co.

Infrastructure Thesis & Sovereign Supply Chain Strategy

Investors acquire, ”equity” common stock in PharmAGRI, and the structured exit strategy is triggered once the investor’s I-829 petition is approved by USCIS. At that time, investors may sell their shares, with the final value potentially exceeding or falling below the original investment, in accordance with market conditions and applicable regulations.

PharmAGRI Capital Partners Co. is a sovereign infrastructure sponsor and public company architecting the complete onshoring of America's plant-based pharmaceutical supply chain. PharmAGRI acts as a banker, deploying capital it raises from different sources.

PharmAGRI Capital Partners Co., a Delaware corporation (the “Partnership” or “New Commercial Enterprise” or “NCE”), will deploy up to $5.5 billion in capital expenditures to build 5,000 acres of Controlled Environment Agriculture (CEA) greenhouses paired with DEA-registered SuperPharm facilities to produce Schedule II-V prescription drugs from domestically grown biomass. A portion of this capex may be funded through EB-5 equity investment proceeds, deployed via PharmAGRI Upstream Borrower, LLC into PharmAGRI Investors LLC (the “Job-Creating Entity” or “JCE”).

PharmAGRI acts as the banker-loaning capital to American farmer-owned operations, securing assets, and recycling repayments into new farm-based infrastructure. All biomass is contracted on a per acre basis annually and delivered to PharmAGRI Superpharm, controlled facilities for API conversion and dosage manufacturing. Manufacturing is executed by affiliates acquired via Drugs Made in America Acquisition Corp I-VI, that could foster the PharmAGRI plan adding expertise and experience compensated by a percentage of sales with federal procurement contracts anchoring revenue from VA, DOD, and HHS.

PharmAGRI's capital engine integrates, private placement, and earned revenue, with investors receiving equity and public market liquidity. The model yields $10B in annual sales with $5.9B in gross profit, secured by DEA quota, federal contracts, and board-controlled governance. Phase II will expand into food sovereignty infrastructure, reinforcing PharmAGRI's role as the sovereign infrastructure bank for food and medicine.

EB-5 Strategy: Global Signal, Not Capital Dependency

PharmAGRI's EB-5 program is designed to enhance global visibility, diversify investor participation, and signal international recognition—not to serve as the sole or primary source of capital.

The Project is not dependent on full EB-5 visa subscription or job count monetization

EB-5 investors will purchase preferred equity in the public company, with conversion rights and governance protections

Participation by immigration investors reinforces PharmAGRI's global relevance and sovereign mission, attracting international partners and amplifying brand equity

EB-5 capital is a strategic complement, not a prerequisite

EB-5 capital expands PharmAGRI's reach for various forms of capital including NASDAQ opportunities while preserving execution independence

Mission-Critical National Asset

PharmAGRI is a bold, federally integrated infrastructure initiative to restore U.S. pharmaceutical and agricultural sovereignty. The project will:

- Build DEA-approved Controlled Environment Agriculture (CEA) greenhouses, GMP manufacturing, and Schedule I–V processing facilities
- Deploy robotics and compliance automation to transform farm labor into high-value pharmaceutical roles
- Anchor a secure, vertically integrated supply chain for plant-based prescription drugs, displacing imports and securing quota

Immediate Goals

- NASDAQ listing
- USDA guarantees to back stop the capital loaned to farmers
- Immediate capital to complete the PharmAGRI acquisitions to onshore foreign companies that are well developed in controlled substances
- Contract supply agreements and infrastructure loans to American farmers that will participate in this first in the
- U.S. production of controlled substances for API and drug manufacturing
- DMAA I-IV acquisition team to use the capital raised, identify targets that align with this platform and commence the buy-out of well managed revenue generating companies in this pharmaceutical space

Strategic Acquisitions

PharmAGRI will acquire and integrate globally recognized DEA-registered entities, including:

Entity	Country	Strategic Role
Alcaliber	Spain	Opium alkaloids, global DEA quota
Extractas Bioscience	Australia	Cannabis APIs, Schedule III molecules
Noramco	U.S.	Synthetic precursors, Schedule II APIs
Bright Green Corporation	U.S.	DEA-registered Schedule I facility, EB-5 Regional Center

These acquisitions have agreed to sell their companies, this opportunity will ensure control over precursor synthesis, API manufacturing, and DEA quota stewardship, enabling PharmAGRI to meet domestic and international demand.

Capital Stack Logic

Source	Role
Public Equity Offering (NASDAQ)	Institutional and retail capital; growth financing
EB-5 Equity Investment (portion of $10B capex)	Strategic global signal; job creation; investor diversity
Debt Financing / USDA Guarantees	Farmer-owner infrastructure; robotics deployment
M&A Synergies	Revenue-generating assets; quota and IP acquisition

Public Company Strategy

PharmAGRI will operate as a NASDAQ-listed public company, leveraging capital markets to:

- Sell equity and raise institutional capital
- Finance farmer-owner-operators to build sovereign infrastructure
- Procure raw materials via USDA contracts and DEA quota allocations
- Manufacture APIs and finished drugs for federal agency procurement and exportv

PharmAGRI's sovereign thesis centers on a vertically integrated, federally aligned lifecycle for plant-based prescription drugs—executed entirely on U.S. soil. By combining DEA-authorized molecule production, climate- controlled biomass cultivation, and GMP-certified drug formulation, PharmAGRI eliminates foreign dependency and reclaims pharmaceutical autonomy. This seed-to-prescription model ensures purity, traceability, and compliance at every stage, positioning the platform as a national asset in controlled substance manufacturing and distribution.

Strategically, PharmAGRI anchors itself within federal procurement pipelines and DEA quota systems, securing long-term access and export authority under FDA protocols. Its infrastructure displaces imported APIs and finished drugs, reinforcing domestic control and readiness for public health emergencies. As geopolitical tensions and supply chain vulnerabilities escalate, PharmAGRI's sovereign architecture offers a resilient, federally compliant solution to restore U.S. pharmaceutical sovereignty and catalyze a new era of Drugs Made in America.

The Regional Center: The Project is located _____________, within the approved geographic designation of Bright Green Regional Center, a USCIS-approved EB-5 Regional Center (the "Regional Center"). The Regional Center's USCIS approval letter is attached hereto as Exhibit 3.

Geographic Locations and Industries: The Project will create jobs in the following industries:

NAICS Industry Industry	
325412	Pharmaceutical Preparation Manufacturing
111419	Other Food Crops Grown Under Cover
115112	Soil Preparation, Planting, and Cultivating
541714	Research and Development in Biotechnology (except Nanobiotechnology)
236220	Commercial and Institutional Building Construction
493120	Refrigerated Warehousing and Storage
561110	Office Administrative Services

Project Costs & Capitalization: Total costs borne by the Project are $14,000,000,000.

Construction Costs	Amount
Nutrition CEA Facilities	$6,800,000,000
Pharma CEA Facilities	$1,100,000,000
SuperPharm Facilities	$2,200,000,000
Other Equipment	$1,000,000,000
Working Capital	$2,898,350,000
Start-up Expenses	$1,650,000
Total	**$14,000,000,000**

Project Development Schedule:

The time frame to complete the Project's design, acquisition, development and production sites is expected to be 3 years (36) months. The Project Company anticipates substantial completion in 2027. Ground-breaking operations began in 2026.

(See Exhibit 4, Preliminary Construction Schedule)



Job Creation: According to the economic analysis conducted by ________________ (the "Economic Consultant"), the Project will create more than 100,000 EB-5 eligible jobs as a result of this project. Up to ten thousand (10,000) EB-5 lenders will be sought to meet the EB-5 loan amount of up to ten billion dollars ($10,000,000,000), so each EB-5 lender will be assigned 10 jobs. *(See Exhibit 2, An EB-5 Economic Analysis of the Development and Operations of PharmAGRI).*

TEA Designation:

TBD

Project Structure and Capitalization

The following is a summary of operational entities involved in the Project and each entity's respective role.

The Partnership	PharmAGRI Capital Partners Co.
Registered As:	Delaware Corporation
Principal Members:	Ms. Lynn Stockwell
Function/Operational Role:	Fund the Project
The Manager of the Partnership:	PharmAGRI Manager, LLC
Registered As:	Limited Liability Company
Function/Operational Role:	Management of the Partnership
Function/Operational Role:	Will manage the Development and build-out of the Project
The Operator:	PharmAGRI Investors LLC
Principal Members:	Ms. Lynn Stockwell
Registered As:	Delaware Limited Liability Company
Function/Operational Role:	Will operate the facilities
The Project Company:	PharmAGRI Investors LLC
Registered As:	Delaware Limited Liability Company

(See **Exhibit 6** *PharmAGRI Capital Partners Co. - Proposed Entity Structure*)

Limited Partnership:	• Formation of a new commercial enterprise, PharmAGRI Capital Partners Co. (to accept up to ten thousand (10,000) EB-5 Investors representing up to $10,000,000,000 of EB-5 investment) • PharmAGRI Manager, LLC will serve as the General Partner
Source of Funds:	• The General Partner conducts its internal due diligence regarding the lawful source of funds
Investment of Capital	• The Partnership shall loan capital to the Upstream Borrower, which shall contribute the EB-5 capital to the Project Company • The total amount of EB-5 loans raised for the Project is at risk
Job Creation:	• Based on an economic impact analysis prepared on behalf of the Partnership, the Project will create 100,000+ jobs • Development of the production site will last 36 months, and funds will be spent in the timeframe required by USCIS to create these jobs
Verification:	• The Regional Center will prepare evidence of EB-5 capital expenditures and revenues generated over the 2-year conditional period of residency to validate the required job creation when submitting I-829 Petitions.

A description of the business, its products and/or services, and its objectives.	Section 2
A market analysis, including the names of competing businesses and their relative strengths and weaknesses. A comparison of the competition's products and pricing structures.	Sections 4 and 7
A description of the new commercial enterprise's target market/prospective customers.	Section 5
A list of required permits and licenses obtained.	Section 2.3
A discussion of the business's marketing strategy, including pricing, advertising, and servicing.	Section 8
An explanation of the business's staffing requirements, a hiring timetable, and job descriptions for all positions.	Section 2.4
The business's organizational structure and its personnel/ management experience.	Section 3
Sales, cost, operating expense and income projections.	Section 9

The Project

PharmAGRI Capital Partners Co. is a Delaware corporation formed to build a $14 billion, federally aligned pharmaceutical and agricultural infrastructure platform that restores U.S. sovereignty over plant-based prescription drug production. Through a combination of strategic acquisitions, DEA quota stewardship, and advanced Controlled Environment Agriculture (CEA), PharmAGRI will vertically integrate the entire seed-to-prescription drug lifecycle.

$14 billion

target value of PharmAGRI's pharmaceutical and agricultural infrastructure platform.

$10 billion

projected capital expenditure for building the platform.

A portion of the $10 billion capital expenditure may be funded through EB-5 equity investment proceeds, deployed via PharmAGRI Upstream Borrower, LLC into PharmAGRI Investors LLC, the Job-Creating Entity (JCE). EB-5 investors will purchase preferred equity in the public company, gaining exposure to a mission-critical enterprise with global relevance.

PharmAGRI's EB-5 strategy is opportunistic, not essential—designed to signal international recognition, diversify investor participation, and amplify global reach. The project is not dependent on full visa subscription or job count monetization.

PharmAGRI will operate as a NASDAQ-listed public company, acting as both sponsor and banker to finance farmer-owner-operators who build sovereign infrastructure. The company will procure raw materials via USDA contracts and DEA quotas, manufacture APIs and finished drugs under GMP standards, and supply federal agencies through secure procurement channels.

By acquiring DEA-registered entities—including Alcaliber (Spain), Extractas Bioscience (Australia), Noramco (U.S.), and Bright Green Corporation (U.S.)—PharmAGRI will control precursor synthesis, API manufacturing, and quota allocation. This positions the company to displace imports, secure federal contracts, and anchor national pharmaceutical resilience.

With a $10 billion capital expenditure pipeline, the Company is executing a modular infrastructure rollout strategy that empowers American farmers, secures DEA-compliant pharmaceutical production, and delivers federally validated job creation metrics.

Valuation Driver	Estimated Value Contribution	Strategic Rationale
DEA Quota-Backed API Supply (5–6 codes)	$2.5B–$3.2B	Quota exclusivity over high-value APIs (Morphine, Thebaine, CBD) enables sovereign supply control.
USDA/HHS Dual Channel Reimbursement Path	$1.2B–$1.5B	Integration into the USDA school lunch and HHS preventive care formulary drives dual reimbursement logic
Tesla Optimus Compliance Automation Grid	$800M–$1.1B	Robotics-enabled stewardship of DEA protocols validates CAPEX while displacing legacy labor.
EB-5 Syndicated Infrastructure Platform	$500M–$750M	Immigrant capital is tied to federal job creation and rural development metrics.
Federal Sovereignty Bank Logic (Charter)	$1.0B–$1.5B	Blueprint for a federal charter bank backed by domestic DEA/USDA/HHS vertical integration
Total Valuation	**$6B–$8B**	**Non-revenue asset logic mapped to federal market control and CapEx triggers**

PharmAGRI is not just building infrastructure—it is underwriting America's pharmaceutical future. Investors are not just funding a company; they are capitalizing a sovereign bank for food and medicine.

Phase I Concentrate on DEA Quota

Completing acquisitions in the DMAA affiliate that will contract for API and drug manufacturing for PharmAGRI contracts

Acquiring and closing the injectable and controlled substance companies

Completing the lease on addition API and generic drug Formulation Licensing

Acquiring rights to use a validated generic drug formula (composition, dosage, delivery method) from the originator or developer.

License the right to manufacture under their ANDA (Abbreviated New Drug Application) or replicate it under PharmAGRI Capital Partners Co., if the patent has expired.

PharmAGRI Quota-Driven Seed-to-Prescription Model (Schedule II-V)

01. DEA Quota Stewardship Backbone

Annual Quota Allocation: Anchored to PharmAGRI's sovereign infrastructure footprint, tied to acreage, job creation, and federal program activation.

Schedule II-V Mapping: Each plant-derived API (e.g., morphine, codeine, dronabinol) mapped to DEA quota class, with conversion protocols and destruction logic embedded.

Quota-Backed Capital Engine: Quota volumes securitized into infrastructure-backed capital pathways (EB-5, institutional equity,IPO capital follow on and federal grants if any).

02. Seed-to-API Infrastructure Logic

Stage	Function	Compliance Overlay
Seed Genetics	Federally registered, Schedule-classified strains	DEA registration, USDA seed certification
Cultivation	Robotics-enabled, CEA-adjacent SuperPharm sites	DEA site registration, biometric access, audit trails
Harvest & Biomass Storage	Controlled environment, real-time inventory	DEA Form 222, destruction protocols, API-on-demand logic
Extraction & API Conversion	cGMP pharma-grade processing	FDA/DEA dual registration, Schedule-specific SOPs
Formulation & Packaging	Schedule II-V drug output (e.g., tablets, oils)	Labeling, serialization, Rx-only protocols
Distribution & Dispensing	Federal procurement, specialty pharmacy, VA channels	DEA 106/222 tracking, PDMP integration

03. Quota-Driven Sovereignty Outcomes

Import Displacement: Each quota tranche replaces foreign API imports, tracked via DEA and CBP data.

Federal Activation: Infrastructure tied to federal programs (VA, HHS, DoD) for direct procurement.

Circular Supply Chain: Biomass-to-API-to-dosage loop with destruction, reallocation, and quota renewal logic.

04. Capital & Governance Integration

Investor Pathways: EB-5 preferred equity, institutional tranches, sovereign co- investment.

Board Oversight: Common control across SPACs, acquisitions, and SuperPharm Storage and API and Finished Drug Manufacturing.

Audit Resilience: Robotics, biometric access, and AI-controlled compliance logs.

PharmAGRI TAM Revenue Model (Schedule II–V Plant- Based Rx)

01. TAM Definition

Scope: U.S. demand for Schedule II-V plant-derived APIs (e.g., morphine, codeine, dronabinol, psilocybin, ketamine analogs)

Use Cases: Pain management, neurology, psychiatry, oncology, palliative care

Channels: VA, DoD, HHS, CMS, specialty pharmacy, federal procurement

02. Market Benchmarks

Drug Class	Est. U.S. Annual Spend	Plant-Based Penetration Potential
Schedule II (e.g., morphine)	$6B+	40-60% via quota-backed domestic API
Schedule III (e.g., dronabinol)	$2B+	70-90% with DEA quota and CEA adjacency
Schedule IV-V (e.g., ketamine analogs, cough suppressants)	$4B+	30-50% with federal alignment

$12B-$15B annually

Estimated TAM

50-70%

Quota-Driven Capture Potential (with full infrastructure deployment)

03. Revenue Model (Quota-Backed Infrastructure)

Component	Revenue Driver	Annual Potential
Cultivation	Biomass yield per acre × DEA quota value	$500M-$1B
API Conversion	API output × Schedule class pricing	$2B-$4B
Dosage Formulation	Rx units federal reimbursement rates	$3B-$5B
Federal Procurement	Direct contracts (VA, DOD, HHS)	$1B-$2B
Specialty Distribution	High-margin Schedule II-III Rx	$1B-$2B

$7.5B-$14B annually

Total Revenue Potential (with full quota utilization)

04. Capital Multipliers

- Quota-Backed Equity: Infrastructure tied to DEA quota yields 3-5x valuation uplift
- Federal Contracts: Multi-year revenue guarantees enable debt structuring
- EB-5 & Sovereign Co-Investment: Job creation and federal overlays unlock non- dilutive capital

PharmAGRI Sovereign CEA Infrastructure Model

$5.5B
Capex

5,000
Acres

3-Year
Build

40%
Alkaloid Predictability

01. Infrastructure Logic Phase ONE Pharma

Component	Metric	Notes
Total Acreage	5,000 acres	CEA greenhouses with artificial lighting
Capex per Acre	$1.1M	Includes robotics, compliance automation, and alkaloid optimization
Crop Cycles	4 per year	Enabled by artificial lighting and climate control
Alkaloid Predictability	40%	Standardized yield across Schedule II–V APIs
Ownership	American farmers	Structured equity co-ownership to ownership

02. Capital Structure

PharmAGRI Capital Partners anchors the financing, with diversified pathways:

Private Placement: Institutional tranches tied to DEA quota and federal overlays

IPO (Future Liquidity): Optional exit for early investors, not relied upon

EB-5 Program: Job creation indices and federal overlays unlock non-dilutive capital

Non-Reliance Clause: Capital is raised to an unknown extent, but deployment proceeds regardless

03. Output & Revenue Potential

Metric	Value	Notes
Annual Crop Output	20,000 cycles	4 crops × 5,000 acres
Alkaloid Yield	40% predictability	Enables DEA quota modeling and API conversion
API Conversion	Schedule II–V	Morphine, codeine, dronabinol, psilocybin, etc.
Revenue Potential	$7.5B–$17.9B annually	Based on dosage form output and federal procurement activation

04. Strategic Outcomes

Sovereign Infrastructure: Farmer-owned, quota-backed, federally activated

Import Displacement: Replaces foreign API with domestic, DEA-registered output

Circular Supply Chain: Biomass-to-API-to-dosage loop with destruction and renewal logic

Federal Activation: VA, DoD, HHS procurement channels embedded

Capital Structure Statement (PharmAGRI Sovereign Infrastructure)

PharmAGRI Capital Partners anchors the infrastructure buildout with a sovereign-first capital strategy. While EB-5 capital is raised to an unknown extent, deployment proceeds regardless — ensuring that federal alignment, DEA quota stewardship, and infrastructure sovereignty are never contingent on investor participation.

Structured Capital Logic

Primary Capital Engine: Quota-backed infrastructure financing led by PharmAGRI Capital Partners

EB-5 Program: Activated for job creation and federal overlays; non-dilutive and additive, not relied upon

Private Placement: Institutional tranches tied to DEA quota, federal procurement, and Schedule-class output

IPO Pathway: Optional liquidity event for early stakeholders; not foundational to deployment

Farmer Ownership: American farmers hold equity or leasehold interest in CEA sites, reinforcing domestic control;

Strategic Pillars

DEA Quota Stewardship: Exclusive control and deployment of DEA manufacturing quotas across a national network of federally registered facilities.

USDA Contracting & Loan Guarantees: Anchored b cutter 100-acre-per- farmer CEA pilots, backed by US guarantees and national food supply contracts.

EB-5 Capital Integration: Job creation and immigrant investment embedded into sovereign infrastructure, accelerating federal program activation.

Nasdaq Governance: Public market access via PharmAGRI's structure, enabling transparent capital formation and investor protection.

Capital & Returns

- $15B+ Infrastructure Thesis
- Multi-entity capital stack designed to maximize ROI through federal overlays (tax credits, USDA guarantees, EB-5 job creation).
- Investor-Protective Equity Logic
- Preferred structures engineered to anchor federal program eligibility and sovereign lending.
- M&A Engine
- Strategic acquisitions (Bright Green, Alcaliber, Extractas Bioscience, Noramco) consolidate global precursor supply and DEA quota control.

Federal Integration Model

PharmAGRI integrates four federal overlays into one sovereign infrastructure engine:

Federal Agency	Role in PharmAGRI Model
DEA	Quota stewardship for Schedule I-V APIs and biomass
USDA	Contracted cultivation, loan guarantees, and robotics deployment
USCIS	EB-5 job creation, immigrant investment, and regional center activation
SEC/Nasdaq	Public market governance, investor protection, and capital signaling

National Security & Sovereignty Impact

PharmAGRI neutralizes foreign control over critical pharmaceutical and agricultural inputs:

- Displaces Chinese precursor imports through domestic synthesis and DEA-regulated cultivation
- Secures U.S. food supply via USDA-contracted, robotics-enabled cultivation across 40 farms
- Protects DEA-regulated APIs from geopolitical disruption, embargo risk, and supply chain sabotage
- Builds audit-resilient infrastructure that meets federal compliance, labor standards, and GMP protocols

PharmAGRI's Superpharm campus model is the first in the world to scale an integrated system where:

- Raw biomass enters one end, and finished prescription drugs exit the other Cost transparency and compliance are engineered into every step-from cultivation to formulation
- Federal procurement agencies are assured fair cost of goods, Made-in-America quality, and end-to-end traceability

Importantly further strengthen U.S. pharmaceutical sovereignty, PharmAGRI is actively pursuing the acquisition and integration of:

- Alcaliber (Spain) - Europe's largest producer of controlled substances and poppy derivatives
- Extractas Bioscience (Australia) - DEA-compliant manufacturer of Schedule II APIs
- Noramco (U.S.) - Domestic supplier of DEA-regulated precursors and synthetic APIs
- Bright Green Corporation (BGXX) - DEA-registered facility with infrastructure suited for quota-backed expansion and "proof of Concept"

Products and Services

DEA-Compliant Greenhouse Infrastructure

Key Features: Modular, scalable design- Advanced climate, energy, and security systems- Franchise-ready model- Federally aligned with DEA/USDA

Target Market/Clients: Rural franchisees- Federal supply chains- USDA partners

Benefits: Reduces foreign dependency- Job creation in rural America- Controlled API biomass production

CO_2-Based API Extraction & Manufacturing Facilities

Key Features: 50MW energy-backed plants- Supercritical CO_2 closed-loop system- GMP/FDA cGMP validated- Real-time compliance data

Target Market/Clients: Pharmaceutical manufacturers- DEA & FDA agencies- Healthcare innovation labs

Benefits: Domestic API production- Supply chain security- Enables new treatments

Federally Aligned Farmer Franchise Program

Key Features: Turnkey infrastructure kits- Compliance training & audit prep- Biomass buyback agreements- USDA financing integration

Target Market/Clients: USDA-registered farmers- Rural landowners- Federal development zones

Benefits: Federal-aligned rural income- Scalable compliance ecosystem- Long-term processor-grower ties

Compliance-as-a-Service (CaaS) Platform

Key Features: DEA/FDA/GMP documentation- Blockchain chain-of-custody- EB-5 reporting & job tracking- USDA contract navigation

Target Market/Clients: State agencies- Institutional investors- Global pharma entrants

Benefits: Lowers regulatory risk- Simplifies federal reporting- EB-5 fund optimization

EB-5 Infrastructure Investment Vehicles

Key Features: Debt/equity hybrid pools- USCIS-ready documentation- Regional center partnerships- Job impact studies

Target Market/Clients: Foreign investors- Economic development agencies- USCIS regional centers

Benefits: Capital for rural projects- U.S. immigration pathways- Infrastructure acceleration

Government Procurement Integration & API Sa

Key Features: Federal & state contract alignment- GMP-certified APIs- Packaged raw inputs- FDA-regulated pharma products

Target Market/Clients: VA, HHS, Medicaid- USDA relief programs- Clinical labs/CROs

Benefits: Secure revenue from contracts- Replaces foreign APIs- Supports MAHA initiatives

Technology & Robotics Deployment Services

Key Features: AI robotic planting/harvesting- Smart HVAC/irrigation- Potency sensors & surveillance- Integrated dashboard & metrics

Target Market/Clients: PharmAGRI facilities- Franchise partners- Federal pilot programs

Benefits: Boosts yields, lowers labor cost- Maintains DEA compliance- Enables federal job training in tech

PharmAGRI is committed to ensuring fair and sustainable livelihoods for its partner farmers by purchasing 100% of their cultivated biomas. Farmers will receive compensation for total value of all farm outputs under long-term contracts, reducing churn and ensuring a stable, sustainable supply of raw materials for the company.

Milestones

PharmAGRI Capital Partners Co. is structured around a series of critical operational, regulatory, and financial milestones designed to ensure compliance, scalability, and first-to-market advantage in federally backed pharmaceutical-agricultural infrastructure. Below is a comprehensive milestone roadmap outlining the company's achievements to date and its projected deployment timeline.

Completed Milestones (Foundation Phase)

Milestone	Details	Completion Date
DEA Quota Allocation Secured	Federal DEA approval for Schedule II biomass cultivation and extraction secured.	Q3 2025
USDA Supply Chain Alignment Validated	The crop and greenhouse model is aligned with the USDA federal sourcing logic for institutional contracts.	Q3 2025
Import Permit (Schedule II Biomass)	The DEA import license was obtained, allowing temporary sourcing during infrastructure buildout.	Q3 2025
MAHA Robotic Greenhouse Technology Validated	Robotic cultivation and compliance system field-tested and approved for GMP-level operations.	Q2 2026
Flagship Site Identified and Zoned	The first 150-acre site was secured and zoned for DEA manufacturing and agricultural infrastructure.	Q2 2026
Franchise Farmer Onboarding Model Finalized	The legal, operational, and revenue-share structure for farmer partners has been completed.	Q2 2026
EB-5 Capital Structure Approved	The EB-5 regional center alignment and investment structure have been approved and are ready for syndication.	Q2 2026
Federal Advisory Panel Engagement Initiated	Engagement with DEA, USDA, and USCIS advisors for oversight, reporting, and policy interface.	Q2 2026

In-Progress Milestones (Execution Phase) PHARMA

Milestone	Details	Projected Completion
Phase 1 Construction: Cultivation & Extraction Hub	Groundbreaking on DEA-approved greenhouse and CO_2 extraction facility (50MW power capacity).	Q2 2026
Franchise Farmer Network Buildout	The first cohort of 10 franchise growers was onboarded with training, equipment, and compliance systems.	Q2 2026
GMP Facility Commissioning	The final cleanroom buildout and DEA/FDA inspection scheduling were initiated for pharmaceutical production.	Q1 2027
USDA Contract Submissions & Pilot Fulfillment	Submission of USDA proposal for school lunch/nutrition supply; small-batch compliance delivery.	Q1 2027
EB-5 Phase 1 Capital Deployment	The first tranche of foreign direct investment through EB-5 was distributed to construction and operations.	Q1 2027
Government Procurement Integration	Registration in SAM.gov, FedMall, and USDA procurement portals finalized.	Q1 2027

Upcoming Milestones (Expansion Phase) MAHA SCHOOL LUNCH PROGRAM

Milestone	Details	Target Date
National Scaling Blueprint Finalized	Documentation and zoning of 5 additional sites across strategic regions (Midwest, etc.).	Q2 2025
MAHA Robotics Export Certification (USDA/NSF)	Validation for international export and licensing of MAHA systems through USDA/NSF partnerships.	Q2 2025
SaaS Monitoring Platform Launch	Launch of PharmAGRI's compliance and cultivation monitoring software platform for public use.	Q2 2025
Global Licensing and IP Syndication	Patents were filed, and licensing agreements were signed for ag-tech and extraction system replication.	Q3 2025
IPO or Strategic REIT Rollout (Optional Path)	Evaluation of public market entry via infrastructure REIT or biotech IPO strategy.	Q4 2025 / 2026

Tactical Next Steps

Initiative	Lead Team	Timeline	Strategic Outcome
DEA Quota Justification Memos	Strategic Ops	Aug 2025	Quota allocation as CAPEX trigger
CEA Site Activation (USDA)	Compliance & AgTech	Q3–Q4 2025	Federal contract visibility & recurring revenue
Optimus Gen 3+ Deployment	Robotics Integration Test	Nov 2025	Labor-to-logistics conversion & ESG impact
EB-5 Syndication Deck	Investor Relations	Sept 2025	Immigrant investment aligned with federal mandate

Acquisition Pathways by Entity

Company	Current Ownership	Recommended Strategy
Extractas Bioscience	Owned by SK Capital Partners	• Initiate direct negotiations with SK Capital for a strategic buyout or joint venture. • Propose a federal infrastructure overlay that aligns with DEA/USDA mandates to justify valuation. • Offer EB-5 syndication as part of the capital stack to de-risk SK's exit.
Noramco	Also owned by SK Capital Partners	• Bundle acquisition with Extracts for operational synergy. • Highlight PharmAGRI's sovereign infrastructure thesis to appeal to SK's impact investment goals. • Structure deals with milestone-based earnouts tied to DEA quota expansion.
Alcaliber	Historically linked to Spanish pharma groups (e.g., Grupo Juan Abelló)	• Engage through European investment banks or sovereign co-investors. • Propose tech transfer and U.S. federal alignment as part of the acquisition logic. • Consider partial stake acquisition with board representation to ease regulatory concerns.
Bright Green Corporation (BGXX)	Listed Company	• A DEA-registered facility in the U.S. with existing infrastructure suited for quota-backed expansion and "proof of concept" operations.

Site Plan

PharmAGRI will build out a total of 50 facilities to provide fresh produce for students throughout the US (up to 40M+ lunches daily) and provide medicinal plant material to secure a fully vertically integrated production of select medicinal products in the US.

The plan includes a total of 50 facilities – 40 for food production and 10 for medicinal plant production, each facility being approximately 100 acres of growing space. The map below shows the impact area and the approximate location of the developments.



Technical solution, Vegetable/ Berry Production

Vegetable and berry production will be based on high-tech greenhouses using state-of-the-art production methods designed to achieve the highest yield per invested dollar under current market conditions. The 40 facilities will consist of 38 primary production sites and two support facilities dedicated to producing starter material for the 38 facilities.

Each facility follows a “butterfly” layout with four production blocks of approximately 25 acres, sharing a single, centralized support area. Each of the 4 “wings” will focus on either a single crop or compatible crop combinations as determined by similarity in production systems. For budget purposes, the setup consists of:

01. Block for tomato production

02. Block for combined tomato/pepper

03. Block for combined strawberry/cucumber production

04. Block for combined melon/berry and lettuce production



For the initial facilities, starter plants will be sourced from third-party suppliers; however, as the network expands, a dedicated internal facility will supply all starter materials. All production sites will be digitally connected through enterprise-level software that monitors crop performance, safety protocols, and operational efficiency in real time. This controlled, data-driven approach ensures predictable year-round production with consistent quality and safety, setting a higher standard for fresh produce supply.

Technical solution, Medicinal Plant Production

Poppy production will be based on an optimized method that brings the production into a controlled environment, increasing both yields and the security around the production. Although the greenhouses are still categorized as high tech, the equipment is simplified to support an in-soil production.

Each facility will consist of 3 identical blocks, each 33.2 acres. With the increased control, a year-round production is planned with staggered seeding and harvest.

The blocks will be supported by a single pre-conditioning and shipping facility to provide a poppy-straw end product produced under GACP rules.



Greenhouse

The greenhouse will be built in a module of 8.0 m x 5.0 m (approximately 26.2’ by 16.4’) with a column height of 6.0 m (20’). The greenhouse will be subdivided into 8 climate zones for each block without internal walls. The superstructure will be hot-dipped galvanized steel. Glazing system in aluminum. Glass mounted as 4 mm tempered glass. Vents will be 3-panes, staggered without insect netting. There will be a central concrete pathway.

Each of the three blocks will have a fully automated roof washer.

Support Area

The support area will be built with a steel structure with a “Venlo” style roof and an SIP panel on all outer surfaces.

All floors are poured and surfaces treated. The support area will hold:

- Manufacturing space
- Offices, change rooms, lunchrooms
- Irrigation room
- Energy room
- Facilities for shipping and receiving

Licenses and Permits

TBD

Economic Impact and Job Creation

Category	Direct Jobs	Indirect Jobs	Induced Jobs	Total Jobs
Pharma Infrastructure (SuperPharm, API, Dosage)	18,000	12,500	9,000	39,500
DEA Compliance, Quota Stewardship, Robotics	2,500	1,200	800	4,500
Federal Procurement, Logistics, Governance	3,000	1,800	1,200	6,000
Total Phase I Jobs	23,500	15,500	11,000	50,000+

Under the EB-5 Regional Center program, each investor must be credited with **at least 10 full-time U.S. jobs**. Based on historical data from EB-5 economic impact studies:

- A $10 billion capital deployment typically supports **~355,000 U.S. jobs**.
- This includes direct, indirect, and induced employment across construction, robotics, logistics, compliance, and agriculture.

Maximum EB-5 Investment

$1,077,000 each

To calculate the number of EB-5 investors:

$10,000,000,000 / $1,077,000

~ 9,285 investors

This assumes each investor contributes the full qualifying amount and is allocated the minimum 10 jobs required for visa eligibility.

Investor-to-Job Ratio

→ **9,285 investors x 10 jobs = 92,850 minimum jobs required**

- With ~355,000 jobs projected, PharmAGRI's model exceeds the threshold by **~3.8x**, offering a strong buffer for USCIS adjudication and I-829 approvals.

The feasibility of PharmAGRI's EB-5 strategy is exponentially enhanced by USCIS's commitment to **90-day adjudication timelines** for conditional green cards, especially under the **I-526E and I-956F frameworks** for Regional Center investors. Here's why your plan is not just possible, but strategically timed:

Acceleration of Investor Onboarding	Alignment with Federal Infrastructure Goals
• 90-day adjudication means EB-5 investors can receive conditional permanent residency within 3 months, rather than waiting 18–24 months as in prior cycles. • This rapid timeline makes PharmAGRI's offering more attractive to global investors, especially those seeking fast-track access to U.S. residency for family and business mobility.	• USCIS is prioritizing job-creating, federally aligned infrastructure—exactly what PharmAGRI delivers through DEA quota stewardship, USDA overlays, and robotics-enabled compliance. • 355,000+ job creation estimate far exceeds the minimum EB-5 threshold, giving USCIS strong justification for expedited review.

Management

Project Organizational Structure

The Project Company will use the EB-5 loan's proceeds to construct, own, and operate the Project.



PharmAGRI Capital Partners is the New Commercial Enterprise (NCE), which receives EB-5 capital and deploys it via loan agreements to farmer operators/owners. That aligns with USCIS guidelines and offers a clean compliance path. Here's how the model could be framed:

NCE-to-JCE Loan Model: Strategic Flow

01. PharmAGRI Capital Partners (NCE)

- Aggregates EB-5 capital from immigrant investors
- Structures the capital as secured loans to quota-weighted farmer operators/owners
- Maintains fund administration, escrow, and USCIS reporting compliance

02. Farmer Operator/Owners (JCEs)

- Receive loan proceeds to execute USDA contracts and DEA quota-backed production.
- Deploy robotics and automation (e.g., Optimus Gen 3+) to generate qualifying jobs.
- Report job creation metrics back to PharmAGRI Investors LLC for I-829 filings

03. Investor Lifecycle

- EB-5 investors file Form I-526/1-526E upon capital commitment
- Jobs created by farmer operators are tracked and validated by PharmAGRI Investors LLC Upon meeting job thresholds, Form I-829 is filed to remove conditions
- Shares in the NCE are unrestricted, and exit options are offered

Loan Structuring Considerations

- Term: Typically, 5-7 years with optional extensions
- Collateral: DEA quota allocations, USDA contracts, and equipment assets
- Interest Rate: Modest, to preserve job creation and project viability
- Covenants: Job creation benchmarks, quota compliance, and federal reporting

Governance Logic: EB-5 Capital Flow & Oversight

Entity	Role	Responsibilities
PharmAGRI Capital Partners (NCE)	Capital Aggregator	- Receives EB-5 funds from immigrant investors - Structures secured loans to farmer operators/owners (JCEs) - Maintains escrow, fund flow, and USCIS compliance - Execute DEA quota-backed production and USDA contracts
Farmer Operator/Owners (JCEs)	Job Creators	- Deploy robotics and automation to generate qualifying jobs - Report job creation metrics to PharmAGRI Investors LLC - Administers loan agreements and monitors capital deployment
PharmAGRI Investors LLC	Compliance Coordinator	- Aggregates job creation data across JCES - Coordinates USCIS filings (1-526/1-829) - Manages investor dashboards and shares unrestricted lifecycle

Governance Flow



Governance & Investor Protection

PharmAGRI's governance model is designed for federal alignment and investor protection:

- Independent board with expertise in DEA, USDA, robotics, and public markets
- Nasdaq governance protocols, EB-5 compliance, and quota stewardship oversight Capital stack structured to maximize federal monetization and minimize investor risk
- Legacy equity in BGXX restructured via RSA, creditors paid in full, and control consolidated for federal integration

The Company's governance logic is built to withstand audit, attract institutional capital, and serve as a model for sovereign infrastructure deployment.

Key Management



Mr. John Stockwell

Mr. John Stockwell will play a crucial leadership role in overseeing the PharmAGRI Capital Partners Co. project, providing strategic guidance and direction to ensure its successful execution. With a strong emphasis on project oversight, Mr. John will manage all aspects of planning, development, and implementation, ensuring alignment with PharmAGRI Capital Partners Co.'s objectives and stakeholder expectations.

Serving as the primary point of contact, he will maintain open and effective communication channels, addressing inquiries, providing updates, and fostering positive relationships with investors, regulatory authorities, and development partners.

Leveraging his expertise in financial management, Mr. John will ensure sound fiscal planning, budgeting, and resource allocation while closely monitoring project finances to mitigate risks and deviations. His leadership and proficiency will drive the Project forward, ensuring adherence to legal and regulatory requirements while promoting transparency, accountability, and stakeholder satisfaction. Mr. John's involvement will be instrumental in advancing PharmAGRI Capital Partners Co.'s mission to deliver exceptional results.

New Positions to be Created

The following 13 new job positions will be created at the Head Office up to Year 5. Job Descriptions of the main roles are provided in Appendix I.

Sr. No.	CEO / General Manager	Year 1	Year 2	Year 3	Year 4	Year 5
1	CEO / General Manager	1	1	1	1	1
2	Regulatory Affairs Officer	1	1	1	1	1
3	CFO	1	1	1	1	1
4	Farm Manager	1	1	1	1	1
5	Agricultural Technicians	10	10	11	11	12
6	Agronomist	2	2	2	2	2
7	Pharmaceutical Scientist	5	5	6	7	8
8	Biochemist	3	3	3	3	3
9	Lab Technician	6	6	8	9	10
10	Sales & Marketing Manager	2	2	2	2	2
11	Supply Chain Manager	2	2	2	2	2
12	CMO	1	1	1	1	1
13	Accounting/Bookkeeping Staff	5	7	9	11	12
14	Support Staff	15	22	28	34	42

Organizational Chart



EB-5 Regional Center

As an EB-5 Regional Center, Bright Green plays a vital role in facilitating the investment process for PharmAGRI Capital Partners Co. and ensuring compliance with the requirements of the EB-5 Immigrant Investor Program. Below is an overview of the responsibilities and functions of regional center management:

Eb-5 Program Compliance: Bright Green Regional Center ensures strict adherence to all regulations, policies, and guidelines set forth by the United States Citizenship and Immigration Services (USCIS) for the EB-5 Immigrant Investor Program. This includes preparing and submitting required documentation, reports, and filings to USCIS, such as Form I-924, Form I-526, and Form I-829, in a timely and accurate manner.

Investment Project Oversight: Comprehensive due diligence is conducted on PharmAGRI Capital Partners Co. to evaluate its suitability as an EB-5 investment project. Factors such as financial viability, job creation potential, and compliance with EB-5 Program requirements are thoroughly assessed. Robust monitoring mechanisms are implemented to track the progress, performance, and compliance of the PharmAGRI Capital Partners Co. project throughout its development and operational phases.

Investor Relations: The Regional Center provides prospective EB-5 investors with clear and accurate information about the investment opportunity presented by PharmAGRI Capital Partners Co., including project specifics, financial projections, and potential risks. Ongoing communication is maintained with EB-5 investors to address inquiries, provide updates on project milestones, and ensure transparency throughout the investment process.

Legal And Compliance Oversight: The Regional Center collaborates closely with legal counsel specializing in immigration law, securities law, and pharmaceutical manufacturing laws to meet all legal and regulatory requirements associated with the PharmAGRI Capital Partners Co. project. It mitigates legal and compliance risks by implementing appropriate safeguards and ensuring full compliance with relevant laws and regulations.

Investor Immigration Process Assistance: Bright Green Regional Center provides comprehensive support and guidance to EB-5 investors throughout their immigration journey. This includes assisting with the preparation and filing of Form I-526 petitions, documentation submission, and conditional permanent residency application procedures. The Regional Center also facilitates the timely and successful completion of Form I-829 petitions for investors seeking to remove conditions on their permanent residency status, ensuring the provision of necessary documentation and ongoing support.

Economic Consultant



Pharmaceutical Manufacturers

Revenue	Employees	Businesses
$302.9bn	**260k**	**1997**
'20-'25 ↑5.8 %	'20-'25 ↑4.8 %	'20-'25 ↑4.3 %
'25-'30 ↑3.4 %	'25-'30 ↑3.8 %	'25-'30 ↑4.2 %

Profit	Profit Margin	Wages
$49.7bn	**16.4%**	**$29.8bn**
'20-'25 ↓1.2 %	'20-'25 ↓6.7 pp	'20-'25 ↑2.4 %
		'25-'30 ↑3.7 %

Revenue for pharmaceutical manufacturers in the U.S. has been growing at a CAGR of 5.8% over the past five years to an estimated $302.9 billion, including expected growth of 3.7% in 2025.

One of the most notable pieces of regulation to date impacting brand-name pharma producers is the Inflation Reduction Act (IRA). Passed in 2022, the IRA introduces multiple provisions impacting the industry, permanently reshaping how pharmaceutical manufacturers will operate. Key provisions of the IRA include Medicare's ability to negotiate drug prices, rebates for excessive price increases and an out-of-pocket spending cap. While a substantial body of criticism and legal challenges surrounding the IRA exists, it marks a movement to lower drug spending for patients and the federal government.

While brand-name pharma manufacturers will navigate an evolving environment, the industry's performance will remain robust. Ongoing R&D investments will yield new, innovative therapies to address unmet needs, bolstering product pipelines. At the same time, an increasing prevalence of chronic illness and a growing number of over-65 adults will support a steep demand for prescription drugs. Merger and acquisition activity seen in recent years won't slow as incumbents look for ways to diversify pipelines, access new technologies or reach new markets as pressures from patent cliffs and the regulatory landscape mount. Still, revenue growth will be strong, increasing at a CAGR of 3.4% to an estimated $358.1 billion over the next five years.

Patent expirations will characterize brand-name pharmaceutical manufacturing over the next five years, with over $300 billion at risk between 2025 and 2033. The scale of patent losses will push pharmaceutical companies to continue exploring ways to compensate for these declines, either by launching new drugs, expanding into different therapeutic areas or exploring new business models

Bringing a new drug to market can take years and billions in R&D spending, which will maintain the industry's trend of M&A in innovative areas like oncology and weight loss drugs. Pharmaceutical companies will likely seek acquisitions that add to strategic areas that complement their existing strengths and capabilities. Investments in areas that naturally align with ongoing initiatives can reduce the time and cost associated with bringing new drugs to market.

A shift in dealmaking was seen in 2024 – the value of M&A dropped 8% according to data from PwC – and could reverse between 2025 and 2030. Economic uncertainty, high interest rates, tighter regulatory scrutiny and a period of active deals between 2021 and 2022 contributed to the slowdown in 2024. Clearer economic conditions, lower interest rates and expectations of more lenient antitrust actions from the Trump Administration would create an environment that incentivizes M&A moving forward.

The slowdown in deal value in 2024 also leaves branded manufacturers with more capital set aside to pursue M&A. A 2024 article from

Major Markets Segmentation

Industry revenue in 2025 broken down by key markets.



Products & Services Segmentation

Industry revenue in 2025 broken down by key product and services lines.



IBISWorld

Source: IBISWorld

A Closer Look at PharmAGRI

PharmAGRI is strategically positioned at the intersection of three urgent macroeconomic trends that are reshaping the pharmaceutical, agricultural, and infrastructure sectors. These trends reveal both vulnerabilities in the current U.S. supply chain and lucrative opportunities for disruptive, compliant, and domestically rooted solutions like those offered by PharmAGRI.

01. Reshoring Pharmaceutical Supply Chains

Market Urgency:

The United States is heavily reliant on imported plant-based Active Pharmaceutical Ingredients (APIs), particularly for Schedule II controlled substances such as opioids. According to the U.S. Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA), approximately **80% of APIs used in U.S. drug manufacturing are imported**, primarily from India and China. This reliance creates a serious national security risk, as highlighted during the COVID-19-era supply chain disruptions and ongoing geopolitical instability.

Market Opportunity:

- Over **$12 billion** in annual imports of plant-derived pharmaceutical products.
- DEA and the Department of Health and Human Services (HHS) initiatives now emphasize **domestic sourcing mandates** for critical substances.
- Legislation like the American Made Pharmaceuticals Act and **Executive Orders on supply chain resiliency** continue to fuel momentum for U.S.-based pharmaceutical cultivation and manufacturing.

PharmAGRI's Positioning:

PharmAGRI is among the **first DEA-quota backed operators** deploying modular, Schedule II-compliant greenhouses combined with robotic cultivation and domestic CO_2-based API extraction. Its vertically integrated model directly aligns with federal reshoring initiatives, ensuring both compliance and sovereign pharmaceutical capacity.

02. Infrastructure Deficit in Controlled-Substance Production

Market Gap:

Despite rising demand and federal push for domestic pharmaceutical production, the infrastructure to produce Schedule II substances within the United States is severely lacking. DEA quotas are not matched by operational capacity.

Key Figures:

Fewer than **five fully operational DEA-compliant biomass processors** currently exist in the U.S.	No domestic extraction facilities have yet achieved **50MW-scale production** using CO_2-based green chemistry.	The limited availability of compliant infrastructure has **restricted investor entry** into this space, despite strong federal and institutional interest.

PharmAGRI's Strategic Edge:

PharmAGRI combines DEA import/export authority, USDA contract logic, and **EB-5 financing models** to offer a replicable, scalable infrastructure blueprint. Its facilities are designed for high-throughput, quota-aligned manufacturing, making it a **first mover** in a market otherwise underserved by compliant infrastructure.

03. Agricultural Labor Crisis & Automation Demand

Market Dynamics:

U.S. agriculture is facing a chronic labor shortage driven by an aging workforce, immigration constraints, and rising compliance costs. The greenhouse sector, in particular, is transitioning toward **ag-tech and robotic solutions** to ensure year-round production and reduce reliance on unpredictable manual labor.

Trends Supporting Automation:

USDA moving toward **contract-based sourcing from automated greenhouses.**	Sharp increase in **VC and institutional investment in ag-tech robotics**—including automated trimming, climate control, yield forecasting, and compliance monitoring.	Investors now favor **capital expenditure (CapEx)-heavy, automation-led models** over variable, labor-intensive operations.

PharmAGRI's Response:

PharmAGRI deploys the **MAHA (Modular Automated High-Availability) greenhouse system**, which reduces labor dependency and improves operational consistency. This positions PharmAGRI as a resilient and scalable solution for year-round, federally compliant pharmaceutical crop production.

Competitive Landscape & Growth Outlook

The **global pharmaceutical API market** is projected to reach **$316 billion by 2030**, with plant-derived APIs making up a significant and growing portion of that figure.	The **U.S. controlled-substance pharmaceutical manufacturing market** remains in early stages of reshoring, offering a multi-billion-dollar white space for early entrants like PharmAGRI.	Ag-tech and greenhouse automation markets are expected to grow at a **CAGR of 10–14%,** further validating PharmAGRI's investment in robotic infrastructure.

Target Addressable Market

Target Market

PharmAGRI Capital Partners Co. operates within a highly specialized intersection of federal infrastructure, pharmaceutical manufacturing, and agricultural policy. Its target market is composed of both public-sector partners and private-sector stakeholders who are seeking federally compliant solutions for domestic pharmaceutical production, controlled agricultural inputs, and rural economic development.

Target Addressable Market (TAM)

Category	Estimated Annual Spend (2025)	Notes
Opioid derivatives (e.g., morphine, codeine)	**$12B+**	Derived from poppy; used in CMS reimbursements, VA, DoD
Cannabinoid-based therapies (CBD, THC)	**$4.5B+**	Medicaid, VA, and state-level medical programs
Psychedelic botanicals (psilocybin, ibogaine)	**$1.2B+**	Emerging spend via NIH, HHS pilot programs
Plant-based precursors for synthetic APIs	**$6B+**	Includes DEA Schedule II/III inputs for domestic manufacturing
Total TAM (Plant-Based Only)	**$24B+**	Federally reimbursed or state-funded procurement

U.S. Federal Agencies and Programs

PharmAGRI directly aligns with and serves several federal mandates. These agencies are not only regulatory stakeholders but also end-users and contracting clients:

U.S. Drug Enforcement Administration (DEA)

- Target: Quota management, Schedule II API production, and licensing of high-security Rx facilities.
- Need: Domestic pharmaceutical manufacturing capacity with DEA compliance.

U.S. Department of Agriculture (USDA)

- Target: Contracted food supply chains (e.g., National School Lunch Program).
- Need: Federally sourced, safe, and healthy crop inputs from domestic growers.

U.S. Citizenship and Immigration Services (USCIS) – EB-5 Program

- Target: Infrastructure projects that meet EB-5 investment criteria for foreign investors.
- Need: High-compliance, job-creating, and shovel-ready infrastructure projects with national significance.

Department of Health and Human Services (HHS), including the FDA

- Target: Regulatory validation and domestic API alternatives.
- Need: End-to-end traceable and GMP-compliant drug manufacturing solutions.

Institutional And Sovereign Investors

PharmAGRI's vertically integrated model is also designed for sophisticated capital partners seeking structured, impact-aligned investment opportunities.

EB-5 Regional Centers and Immigrant Investors

- Investment Need: Federally pre-approved, job-creating projects.
- Attraction: PharmAGRI's compliant infrastructure creates high EB-5 job multipliers and aligns with national security priorities.

Private Equity & Infrastructure Funds

- Investment Need: Exposure to biotech, agri-tech, and federal-aligned industries.
- Attraction: Government-backed guarantees, stable long-term returns, and regulatory moats.

Sovereign Wealth Funds & Pension Funds

- Investment Need: Long-term ESG-aligned U.S. infrastructure plays.
- Attraction: National health security positioning and USDA/DEA contract backing.

U.S. Pharmaceutical Supply Chain Participants

As domestic pharmaceutical reshoring becomes a national security imperative, PharmAGRI serves key players in the supply chain:

Generic Drug Manufacturers & API Processors

- Need: DEA-approved domestic sources of high-quality Schedule II biomass and intermediates.

Contract Manufacturing Organizations (CMOs)

- Need: Federally secure feedstocks and GMP-aligned facilities for outsourced Rx production.

Healthcare Networks & Government Buyers

- Need: Traceable, U.S.-made pharmaceuticals for hospitals, VA systems, and Medicaid programs.

Agricultural Workforce & Franchise Farmers



PharmAGRI transforms rural employment by creating structured, technology-enhanced farming franchises.

Franchise Farmers

- Need: Turnkey infrastructure, federal market access, and compliance tools.
- Attraction: MAHA greenhouses with robotic farming capabilities and USDA contract alignment.

Rural Communities

- Need: Durable employment, federal wage support, and skills training.
- Attraction: Job creation in GMP manufacturing, agri-tech, logistics, and energy systems.

Technology Providers and Strategic Partners

As an innovation-forward enterprise, PharmAGRI is a valuable customer and collaborator for:

- Automation & Robotics Companies
- CO_2 Extraction Equipment Manufacturers
- Climate Control & Energy Storage Firms
- Agri-Genomics and Crop Engineering Labs

These providers benefit from working with PharmAGRI on high-visibility infrastructure deployments with federal oversight.

Demographic Profile

Category	Key Statistics (2022–2025)	Notes & Trends	Source
Number of Farms	~1.9 million farms (–7% since 2017)	Avg. farm size: ~463 acres (+5%)	USDA NASS 2022 Census[1]
Land in Farms	~880 million acres (–2.2% since 2017)	~20 million acres lost since 2017	USDA NASS
Production Value	$543 billion farm output; net cash income ≈ $152 billion	Avg. farm income ≈ $79,800	USDA ERS
Main Commodities	Corn, soybeans, wheat, and beef cattle	Corn: 15.1 bn bushels; wheat: ~50 Mt/year	USDA, Wikipedia[2]
Farm Labor Force	~2.1 million; crop workers ~1.4–2.1 million/year	~40% undocumented nationally	Wikipedia, The Week
Demographics – Producers	Avg. age: 58.1 years; 296,480 operators under age 35	Beginning farmers are growing, on average. age 47.1	USDA NASS
Gender & Diversity	36% female producers (~1.2 million); 58% of farms have ≥1 female operator	Minority producers declining; Black farmers –8%	USDA, The Guardian[3]
Internet & Renewables	79% of farms have internet; 153,000 use renewables	Solar is most common; +15% since 2017	USDA NASS
Ag-Related Pharma (Animal Health)	10% growth in antibiotic sales since 2017	Shift to vaccines, methane-reducing feed	Vox[4]
Domestic Pharma Manufacturing	$27B invested by Eli Lilly in 4 new U.S. drug plants	Includes API and injectables	NY Post[5]
Pharma Trade Policy Shift	Potential 250% tariffs on drug imports	Aimed to promote U.S. production	Reuters, News.com.au[6]

[1] https://www.nass.usda.gov/Newsroom/2024/02-13-2024.php

[2] https://en.wikipedia.org/wiki/Corn_production_in_the_United_States

[3] https://www.theguardian.com/environment/2024/feb/15/us-agriculture-census-farming

[4] https://www.vox.com/future-perfect/401172/antibiotics-meat-pharmaceutical-industry-agriculture

[5] https://nypost.com/2025/02/26/business/eli-lilly-plans-to-invest-27b-to-build-four-new-us-plants

[6] https://www.reuters.com/business/healthcare-pharmaceuticals/us-initially-impose-small-tariff-pharma-imports-trump-says-2025-08-05

Branding Strategy

Goals

To establish a resilient, secure, and fully compliant domestic pharmaceutical manufacturing infrastructure that reduces U.S. dependence on imported medicinal compounds by producing high-quality, plant-based Active Pharmaceutical Ingredients (APIs) and finished drugs, thereby strengthening national healthcare security and supply chain autonomy.

Key Supporting Objectives:

Reshore Critical Drug Manufacturing:

Focus on U.S.-based production of Schedule II and essential medicines currently imported from foreign sources.

Ensure DEA and FDA Compliance:

Operate fully within federal regulatory frameworks for controlled substance cultivation, extraction, and formulation.

Advance Greenhouse-to-Lab Vertical Integration:

Create a fully integrated supply chain — from controlled-environment agriculture to pharmaceutical-grade manufacturing.

Promote National Health Security:

Serve as a strategic resource for federal and state stockpiles by producing critical APIs domestically.

Innovate Sustainably:

Use modular, energy-efficient infrastructure to ensure cost-effective, scalable production.

Keys to Success

Regulatory Exclusivity: One of the few entities federally licensed for DEA Schedule II cultivation and extraction, ensuring secure access to restricted markets.

Advanced Agri-Tech: Proprietary robotic greenhouse systems and solventless CO_2 extraction enable high-efficiency, pharmaceutical-grade output.

Vertical Integration: Control from seed to shipment, including USDA and DoD supply contracts, ensures consistency, compliance, and profitability.

Franchise Farming Model: Scalable rural deployment creates inclusive growth, workforce development, and rapid expansion potential.

Capital Strategy: Blended financing through EB-5, USDA guarantees, and institutional capital accelerates infrastructure while preserving equity.

Expert Leadership: A seasoned team with experience in federal regulation, pharmaceutical operations, and agri-tech commercialization.

ESG & Job Creation: Committed to sustainable farming, low-emission extraction, and creating certified jobs in underserved communities.

Local Competitive Analysis

Pfizer Inc.

Year Founded: 1849 (Brooklyn, NY)

Headquarters Address: 66 Hudson Boulevard East, New York, NY 10001 2192, USA

Website: www.pfizer.com

Facebook Page: https://www.facebook.com/Pfizer (~239K followers)



Pfizer is a global pharmaceutical leader known for its broad portfolio of small-molecule drugs, vaccines, and gene therapies. It operates major R&D and manufacturing facilities across the U.S., including sectors in rare diseases, metabolic and cardiovascular health, oncology, and vaccines. Recent initiatives include launching PfizerForAll, a digital platform aimed at improving patient access to care, prescriptions, and screenings in the U.S.

Merck & Co., Inc.

Year Founded: 1891 as the U.S. affiliate, independent since 1917

Headquarters Address: 126 East Lincoln Avenue, P.O. Box 2000, Rahway, NJ 07065, USA

Website: www.merck.com

General Inquiry Email:mediarelations@merck.com

Facebook page: https://www.facebook.com/MerckManualHomeUS/

Merck & Co., headquartered in Rahway, New Jersey, is a leading innovator in cancer therapies, vaccines (notably Keytruda & Gardasil), and global health solutions. With a robust U.S.-based manufacturing footprint, Merck plays a critical role in producing biologics and sterile injectables. The company emphasizes addressing public health challenges and widely supports equity-driven patient access programs.

Eli Lilly And Company



Year Founded: 1876, Indianapolis, Indiana, by Colonel Eli Lilly

Headquarters Address: Lilly Corporate Center, 301–325 E. Henry Street, Indianapolis, IN 46285, USA

Website: www.lilly.com

General Inquiry Email: communications_corporate@lilly.com (corporate/general matters)

Facebook Page: https://www.facebook.com/elilillyandco/

Eli Lilly and Company is a top global pharma firm specializing in diabetes, oncology, neurology, and immunology. Known for blockbuster therapies like Humalog, Trulicity, Cymbalta, and Zepbound, Lilly drives both innovative R&D and large-scale U.S.-based manufacturing. The firm also emphasizes patient affordability via programs like LillyDirect® and Lilly Cares Foundation, and maintains strong physician/patient support centers.

Competitive Advantages

The following is a listing of the primary competitive advantages of the Company upon entering the market.

01. Federal Regulatory Positioning

One of the only private entities with aligned DEA and USDA compliance frameworks for dual food and pharmaceutical operations.

02. Vertically Integrated Infrastructure

Full control from cultivation to CO_2-based pharmaceutical manufacturing ensures quality, efficiency, and regulatory alignment.

03. Replicable Franchise Model

Standardized, cookie-cutter farm and greenhouse design enable rapid, scalable deployment nationwide.

04. Dual Market Penetration

Simultaneously serves two federally-backed markets: school nutrition (MAHA program) and DEA Schedule II pharmaceutical production.

05. Sovereign Drug Sourcing

Eliminates U.S. dependence on foreign narcotic imports through climate-controlled, closed-loop production systems.

06. ESG-Backed Job Creation

High-tech, rural job creation meets EB-5 and federal economic development priorities—backed by measurable impact metrics.

07. Capital Stack Innovation

Blends USDA-backed lending, EB-5 funding, and institutional capital to derisk infrastructure investment and ensure long-term sustainability.

08. Technology

PharmAGRI pioneers the deployment of Tesla Optimus robotics for pharmaceutical cultivation, compliance automation, and labor transformation-creating high-value roles for U.S. farm operators and audit-resilient infrastructure.

SWOT Analysis

The following is a listing of the key strengths and weaknesses of North Georgia, as well as the opportunities and threats that exist within the marketplace.

Strengths

- Dual Federal Alignment: Unique integration of DEA and USDA-compliant operations.
- Franchise-Style Deployment: Scalable, standardized infrastructure across farm and pharmaceutical sites.
- Vertical Integration: Control over the entire supply chain—from cultivation to extraction and distribution.
- Federal Contract Access: Tied into school lunch programs (MAHA) and DEA pharmaceutical quotas.

Weaknesses

- Regulatory Complexity: High administrative burden of managing compliance across multiple federal agencies.
- Capital Intensive Model: Requires significant upfront investment in infrastructure and technology.
- Early-Stage Market Identity: Still developing national brand recognition among investors and public agencies.

Opportunities

- Government-Funded Health Programs: Strong alignment with national nutrition and drug sovereignty initiatives.
- Pharmaceutical Independence: Demand for U.S.-sourced controlled substances is rising amid global supply chain risks.
- EB-5 Investment Appeal: High job creation and economic development metrics attract immigrant investor capital.

Threats

- Policy Shifts: Changes in DEA scheduling or USDA school nutrition policy could impact core revenue streams.
- Competitive Entry: Larger pharmaceutical or ag-tech firms may try to replicate or enter the market.
- Operational Risks: Farmer adoption, climate control issues, or system integration failures could impact consistency.

Risk Analysis

Risk	Description	Mitigation
Regulatory Compliance Failure	DEA or USDA non-compliance could result in loss of license, fines, or shutdown.	Employ full-time DEA Compliance Officers and USDA Contract Coordinators with audit protocols.
Operational Downtime	System failure in greenhouses or extraction facilities could halt production.	Redundant systems, robotics maintenance teams, and real-time monitoring software.
Supply Chain Disruption	Input shortages or transportation delays could affect timelines and quality.	Establish multiple supplier contracts and in-house inventory control systems.
Labor Shortage or Misalignment	Difficulty hiring or training for technical roles in rural zones.	Partner with vocational schools, offer federal wage incentives, and certification programs.
Technology Integration Issues	Robotic systems or software may fail to sync across franchises.	Conduct phased deployment, hire Systems Integrators, and run QA simulations before rollout.
Funding Delays or Shortfalls	Delay in EB-5 or institutional capital could stall project timelines.	Diversify funding sources, stage development by priority, and maintain investor pipeline.
Policy or Quota Changes	DEA quota adjustments or USDA program shifts may affect revenue models.	Maintain active policy monitoring and diversify into private sector pharmaceutical contracts.
Climate or Energy Instability	Weather or energy price fluctuations may disrupt greenhouse operations.	Use MAHA structures with internal climate control and long-term energy procurement contracts.

Barriers to Entry

Barrier	Description	Mitigation Strategy
High Capital Requirements	Pharmaceutical manufacturing and DEA-compliant greenhouses demand large upfront investments.	Secure phased investment, explore federal grants (e.g., BARDA, NIH), and use modular, scalable infrastructure.
Regulatory and Permitting	Stringent FDA, DEA, EPA, and USDA compliance requirements slow setup and operation.	Hire regulatory consultants, build early relationships with agencies, and establish a dedicated compliance team.
Brand Affiliation Challenges	Hospitals and buyers prefer established suppliers with known reliability and safety.	Form partnerships or supply to contract manufacturers (CMOs); focus on quality certifications (cGMP, ISO).
Market Saturation	Mature markets for generics and APIs are dominated by large multinationals.	Focus on reshored manufacturing, Schedule II plant-based APIs, and underserved therapeutic niches.
Economies of Scale	Competitors enjoy cost advantages through massive scale and global supply chains.	Leverage vertical integration (cultivation to API), invest in automation, and specialize in short-supply APIs.
Access to Skilled Labor	Shortage of experienced pharma technicians, engineers, and compliance staff.	Partner with universities, offer training programs, and locate near biotech hubs or labor-abundant zones.
Brand Recognition and Trust	New firms lack consumer and regulatory trust, especially in sensitive drug classes.	Invest in transparency, third-party audits, and thought leadership (e.g., publishing, public engagement).
Technological Integration	Integration of lab automation, ERP, and traceability systems is costly and complex.	Adopt flexible, cloud-based platforms early; partner with tech providers offering pharma-ready solutions.
Local Community Acceptance	DEA-regulated cultivation (e.g., poppy, cannabis) may face local resistance.	Launch proactive community outreach, emphasize job creation, and ensure strict site security and compliance.
Supply Chain Dependencies	Reliance on imported precursors and specialized equipment may disrupt timelines.	Diversify suppliers, invest in domestic source partnerships, and maintain strategic inventory reserves.

Marketing Campaign

PharmAGRI Capital Partners Co. will strive to meet the following objectives as it accomplishes specific keys to success:

Target Audience Segmentation

- U.S.- based pharmaceutical companies are seeking domestic API and botanical drug suppliers.
- Government agencies (HHS, DoD, DEA) are prioritizing secure drug sourcing.
- Hospitals and healthcare networks are facing drug shortages or seeking DEA-compliant vendors.
- Strategic investors and partners focused on reshoring critical supply chains.
- Messaging Focus: “Secure. Compliant. American-Made Therapeutics.”

Brand Positioning

PharmAGRI is positioned as **America’s next-generation pharmaceutical cultivator and manufacturer**, offering vertically integrated, DEA-licensed plant-to-drug production for high-value, critical medicines — bridging the national gap between supply security and therapeutic innovation.

Digital Marketing Strategies

- **Website & SEO:** Launch an authoritative site focused on pharmaceutical manufacturing, supply chain resilience, and DEA-compliant cultivation.
- **LinkedIn Campaigns:** Target pharma executives, CDMOs, and health agencies with thought-leadership content and whitepapers.
- **Webinars & Virtual Tours:** Host interactive sessions showcasing PharmAGRI’s technology, facility design, and compliance protocols.
- **Targeted Google Ads:** Bid on reshoring, Schedule II APIs, and botanical drug manufacturing keywords.

Partnerships and Collaborations

- Government Engagement: Pursue strategic partnerships with BARDA, NIH, and DLA to supply essential medicines and APIs.

- University Partnerships: Collaborate on R&D and workforce development with pharmacy and agri-biotech programs.
- CDMO & Pharma Alliances: Partner with U.S.-based drug makers to integrate PharmAGRI as a trusted backend supplier.

Offline Marketing Strategies

- **Trade Shows & Conferences:** Exhibit at CPhI North America, BIO International, and AAPS PharmaSci to build B2B exposure.
- **Direct Outreach:** Deploy targeted account-based marketing (ABM) to hospital procurement teams, GPOs, and state buyers.
- **Whitepaper Distribution:** Publish in industry journals and distribute FDA/DEA compliance roadmaps to build trust.

Loyalty and Referral Programs

- **Preferred Client Program:** Offer volume discounts and early access to high-demand APIs for recurring partners.
- **Referral Incentives:** Create B2B referral bonuses for consultants, CMOs, or agencies that onboard new clients.
- **Compliance Continuity Plans:** Reward long-term clients with guaranteed production slots and support for compliance audits.

Seasonal Promotions

- **"Made in America" Campaign (July):** Emphasize reshored production and national supply chain independence.
- **Q4 Procurement Push:** Target year-end government and hospital buyers with fast-track capacity offers.
- **Earth Month (April):** Highlight sustainable production methods and green infrastructure in Clean Pharma Week.

Measurement and Adjustments

- **Performance Metrics:** Track occupancy rates, website traffic, social media engagement, and campaign ROI.
- **Customer Feedback:** Use guest reviews and surveys to refine offerings and address areas for improvement.

Financial Projections

Administrative Personnel Forecast

The personnel forecast below shows the staffing needs for the next five years.

	Year 1	Year 2	Year 3	Year 4	Year 5
Staff Count					
CEO / General Manager	1	1	1	1	1
Regulatory Affairs Officer	1	1	1	1	1
CFO	1	1	1	1	1
Farm Manager	1	1	1	1	1
Agricultural Technicians	10	10	11	11	12
Agronomist	2	2	2	2	2
Pharmaceutical Scientist	5	5	6	7	8
Biochemist	3	3	3	3	3
Lab Technician	6	6	8	9	10
Sales & Marketing Manager	2	2	2	2	2
Supply Chain Manager	2	2	2	2	2
CMO	1	1	1	1	1
Accounting/Bookkeeping Staff	5	7	9	11	12
Support Staff	15	22	28	34	42
Total Personnel	**55**	**64**	**76**	**86**	**98**
Staff Salary					
CEO / General Manager	$300,000	$309,000	$318,270	$327,818	$337,653
Regulatory Affairs Officer	$250,000	$257,500	$265,225	$273,182	$281,377
CFO	$250,000	$257,500	$265,225	$273,182	$281,377
Farm Manager	$200,000	$206,000	$212,180	$218,545	$225,102
Agricultural Technicians	$90,000	$92,700	$95,481	$98,345	$101,296
Agronomist	$200,000	$206,000	$212,180	$218,545	$225,102
Pharmaceutical Scientist	$180,000	$185,400	$190,962	$196,691	$202,592
Biochemist	$150,000	$154,500	$159,135	$163,909	$168,826
Lab Technician	$70,000	$72,100	$74,263	$76,491	$78,786
Sales & Marketing Manager	$180,000	$185,400	$190,962	$196,691	$202,592
Staff Salary - Total					
CEO / General Manager	$300,000	$309,000	$318,270	$327,818	$337,653
Regulatory Affairs Officer	$250,000	$257,500	$265,225	$273,182	$281,377
CFO	$250,000	$257,500	$265,225	$273,182	$281,377
Farm Manager	$200,000	$206,000	$212,180	$218,545	$225,102
Agricultural Technicians	$900,000	$927,000	$1,050,291	$1,081,800	$1,215,550
Agronomist	$400,000	$412,000	$424,360	$437,091	$450,204
Pharmaceutical Scientist	$900,000	$927,000	$1,145,772	$1,376,836	$1,620,733
Biochemist	$450,000	$463,500	$477,405	$491,727	$506,479
Lab Technician	$420,000	$432,600	$594,104	$688,418	$787,856
Sales & Marketing Manager	$360,000	$370,800	$381,924	$393,382	$405,183
Total Payroll	**$6,005,000**	**$6,673,370**	**$7,756,240**	**$8,723,240**	**$9,897,724**

Personnel Assumptions: (1) Costs are based on average wages.

Revenue Forecast

The following is a five-year revenue and direct cost forecast.

Revenue Forecast

	Year 1	Year 2	Year 3	Year 4	Year 5
Total					
Cultivation	100,000	110,000	121,000	133,100	146,410
API Conversion	20,000	22,000	24,200	26,620	29,282
Dosage Formulation	32,000,000	35,200,000	38,720,000	42,592,000	46,851,200
Federal Procurement	14,000,000	15,400,000	16,940,000	18,634,000	20,497,400
Specialty Distribution	7,500,000	8,250,000	9,075,000	9,982,500	10,980,750
Price					
Cultivation	$5,000.00	$5,000.00	$5,000.00	$5,000.00	$5,000.00
API Conversion	$130,000.00	$130,000.00	$130,000.00	$130,000.00	$130,000.00
Dosage Formulation	$125.00	$125.00	$125.00	$125.00	$125.00
Federal Procurement	$100.00	$100.00	$100.00	$100.00	$100.00
Specialty Distribution	$200.00	$200.00	$200.00	$200.00	$200.00
Revenue					
Cultivation	$500,000,000	$550,000,000	$605,000,000	$665,500,000	$732,050,000
API Conversion	$2,600,000,000	$2,860,000,000	$3,146,000,000	$3,460,600,000	$3,806,660,000
Dosage Formulation	$4,000,000,000	$4,400,000,000	$4,840,000,000	$5,324,000,000	$5,856,400,000
Federal Procurement	$1,400,000,000	$1,540,000,000	$1,694,000,000	$1,863,400,000	$2,049,740,000
Specialty Distribution	$1,500,000,000	$1,650,000,000	$1,815,000,000	$1,996,500,000	$2,196,150,000
Total Revenue	**10,000,000,000**	**$11,000,000,000**	**$12,100,000,000**	**$13,310,000,000**	**$14,641,000,000**
Direct Cost					
Cultivation	$3,800.00	$3,800.00	$3,800.00	$3,800.00	$3,800.00
API Conversion	$96,200.00	$96,200.00	$96,200.00	$96,200.00	$96,200.00
Dosage Formulation	$32.50	$32.50	$32.50	$32.50	$32.50
Federal Procurement	$26.00	$26.00	$26.00	$26.00	$26.00
Specialty Distribution	$52.00	$52.00	$52.00	$52.00	$52.00
Direct Cost of Revenue					
Cultivation	$380,000,000	$418,000,000	$459,800,000	$505,780,000	$556,358,000
API Conversion	$1,924,000,000	$2,116,400,000	$2,328,040,000	$2,560,844,000	$2,816,928,400
Dosage Formulation	$1,040,000,000	$1,144,000,000	$1,258,400,000	$1,384,240,000	$1,522,664,000
Federal Procurement	$364,000,000	$400,400,000	$440,440,000	$484,484,000	$532,932,400
Specialty Distribution	$390,000,000	$429,000,000	$471,900,000	$519,090,000	$570,999,000
Subtotal Cost of Revenue	**$4,098,000,000**	**$4,507,800,000**	**$4,958,580,000**	**$5,454,438,000**	**$5,999,881,800**

Revenue Forecast Assumptions: (1) Revenue and costs are based on averages.

Component	Volume Assumption	Price Assumption	Revenue Range
Cultivation	100,000	$5,000	$500,000,000
API Conversion	20,000	$130,000	$2,600,000,000
Dosage Formulation	32,000,000	$125	$4,000,000,000
Federal Procurement	14,000,000	$100	$1,400,000,000
Specialty Distribution	7,500,000	$200	$1,500,000,000
			$10,000,000,000



Break-Even Analysis

The following break-even analysis shows the revenue necessary to break even in the first year of operation. Break-even is where revenue equals expenses. As shown below, the Company is expected to incur average monthly fixed costs of **$234,425,241** in Year 1. To cover fixed costs and variable costs, which rise and fall with revenue, the Company must, on average, achieve revenue of **$431,883,700** per month to break even.

Year 1 Break-even Analysis

Monthly Revenue Break-even	$431,883,700

Assumptions:	
Average Monthly Revenue	$833,333,333
Average Monthly Variable Cost	$381,002,375
Estimated Monthly Fixed Cost	$234,425,241



Projected Income Statement

PharmAGRI Capital Partners Co. intends to deploy its funding to maximize growth and profitability. Below is the projected income statement of the Company:

Pro Forma Income Statement

	Year 1	Year 2	Year 3	Year 4	Year 5
Revenue	$10,000,000,000	$11,000,000,000	$12,100,000,000	$13,310,000,000	$14,641,000,000
Subtotal Cost of Revenue	$4,098,000,000	$4,507,800,000	$4,958,580,000	$5,454,438,000	$5,999,881,800
Gross Receipts Tax (Delaware)	$12,581,100	$13,841,100	$15,227,100	$16,751,700	$18,428,760
Total Cost of Revenue	$4,110,581,100	$4,521,641,100	$4,973,807,100	$5,471,189,700	$6,018,310,560
Gross Margin	**$5,889,418,900**	**$6,478,358,900**	**$7,126,192,900**	**$7,838,810,300**	**$8,622,689,440**
Gross Margin/Revenue	58.89%	58.89%	58.89%	58.89%	58.89%
Expenses					
General & Admin Expenses	$1,440,000,000	$1,540,000,000	$1,694,000,000	$1,863,400,000	$2,049,740,000
Marketing & Advertising	$500,000,000	$550,000,000	$605,000,000	$665,500,000	$732,050,000
Legal and Professional	$420,000	$430,500	$441,263	$452,294	$463,601
Licensing	$600,000	$615,000	$630,375	$646,134	$662,288
Research and Development	$3,000,000	$3,075,000	$3,151,875	$3,230,672	$3,311,439
Employees Training	$3,600,000	$3,690,000	$3,782,250	$3,876,806	$3,973,726
Travel Related	$6,000,000	$6,150,000	$6,303,750	$6,461,344	$6,622,877
Facility Maintenance	$200,000,000	$220,000,000	$242,000,000	$266,200,000	$292,820,000
Startup Cost	$1,650,000	$0	$0	$0	$0
Depreciation	$555,000,000	$555,000,000	$555,000,000	$555,000,000	$555,000,000
Payroll Taxes	$669,558	$744,081	$864,821	$972,641	$1,103,596
Total Personnel	$6,005,000	$6,673,370	$7,756,240	$8,723,240	$9,897,724
Total Operating Expenses	**$2,716,944,558**	**$2,886,377,951**	**$3,118,930,573**	**$3,374,463,131**	**$3,655,645,252**
Profit Before Interest and Taxes	$3,172,474,343	$3,591,980,949	$4,007,262,327	$4,464,347,169	$4,967,044,188
EBITDA	$3,727,474,343	$4,146,980,949	$4,562,262,327	$5,019,347,169	$5,522,044,188
Interest Expense	$96,158,339	$93,138,251	$89,967,600	$86,638,878	$83,144,205
Applicable Federal Tax	$461,447,400	$524,826,405	$587,594,209	$656,656,244	$732,584,997
Net Profit	**$2,614,868,603**	**$2,974,016,293**	**$3,329,700,518**	**$3,721,052,047**	**$4,151,314,985**
Net Profit/Revenue	26.15%	27.04%	27.52%	27.96%	28.35%

Income Statement Assumptions: (1) Depreciation is based on 20 years; (2) Total payroll taxes are 11.15%; (3) Company taxes are based on 15%.


Gross Margin & Profit Monthly
$700,000,000
$600,000,000
$500,000,000
$400,000,000
$300,000,000
$200,000,000
$100,000,000
$0
-$100,000,000
-$200,000,000
Month 1
Month 2
Month 3
Month 4
Month 5
Month 6
Month 7
Month 8
Month 9
Month 10
Month 11
Month 12
Gross Margin
Profit

Projected Cash Flow

The following is a depiction of PharmAGRI Capital Partners Co.'s projected cash flow:

Pro Forma Cash Flow

	Year 1	Year 2	Year 3	Year 4	Year 5
Cash Received					
Revenue	$9,722,222,222	$10,972,222,222	$12,069,444,444	$13,276,388,889	$14,604,027,778
EB-5 Investors	$10,000,000,000	$0	$0	$0	$0
Federal Loan Guarantee (USDA/DoD)	$2,000,000,000	$0	$0	$0	$0
Private Placement	$2,000,000,000	$0	$0	$0	$0
Subtotal Cash Received	**$23,722,222,222**	**$10,972,222,222**	**$12,069,444,444**	**$13,276,388,889**	**$14,604,027,778**
Expenditures					
Expenditures from Operations					
Total Personnel	$6,005,000	$6,673,370	$7,756,240	$8,723,240	$9,897,724
Bill Payments	$6,144,434,024	$7,490,393,825	$8,162,423,112	$8,955,777,793	$9,848,386,085
Subtotal Spent on Operations	**$6,150,439,024**	**$7,497,067,195**	**$8,170,179,352**	**$8,964,501,033**	**$9,858,283,810**
Additional Cash Spent					
Start-up Costs	$1,650,000	$0	$0	$0	$0
Principal Loan Repayment	$60,578,472	$63,598,560	$66,769,211	$70,097,933	$73,592,606
Purchase Long-term Assets	$11,100,000,000	$0	$0	$0	$0
Subtotal Cash Spent	**$17,312,667,496**	**$7,560,665,755**	**$8,236,948,564**	**$9,034,598,966**	**$9,931,876,416**
Net Cash Flow	$6,409,554,727	$3,411,556,468	$3,832,495,881	$4,241,789,922	$4,672,151,362
Cash Balance	**$6,409,554,727**	**$9,821,111,194**	**$13,653,607,075**	**$17,895,396,997**	**$22,567,548,360**

Projected Balance Sheet

The following is the projected balance sheet for PharmAGRI Capital Partners Co.

Pro Forma Balance Sheet

	Year 1	Year 2	Year 3	Year 4	Year 5
Assets					
Current Assets					
Cash	$6,409,554,727	$9,821,111,194	$13,653,607,075	$17,895,396,997	$22,567,548,360
Account Receivable	$277,777,778	$305,555,556	$336,111,111	$369,722,222	$406,694,444
Total Current Assets	**$6,687,332,504**	**$10,126,666,750**	**$13,989,718,186**	**$18,265,119,220**	**$22,974,242,804**
Long-term Assets					
Long-term Assets	$11,100,000,000	$11,100,000,000	$11,100,000,000	$11,100,000,000	$11,100,000,000
Accumulated Depreciation	$555,000,000	$1,110,000,000	$1,665,000,000	$2,220,000,000	$2,775,000,000
Total Long-term Assets	**$10,545,000,000**	**$9,990,000,000**	**$9,435,000,000**	**$8,880,000,000**	**$8,325,000,000**
Total Assets	**$17,232,332,504**	**$20,116,666,750**	**$23,424,718,186**	**$27,145,119,220**	**$31,299,242,804**
Liabilities and Capital					
Current Liabilities					
Accounts Payable	$678,042,374	$651,958,885	$697,079,015	$766,525,935	$842,927,140
Other Current Liabilities	$10,000,000,000	$10,000,000,000	$10,000,000,000	$10,000,000,000	$10,000,000,000
Subtotal Current Liabilities	**$10,678,042,374**	**$10,651,958,885**	**$10,697,079,015**	**$10,766,525,935**	**$10,842,927,140**
Long-term Liabilities	$1,939,421,528	$1,875,822,968	$1,809,053,757	$1,738,955,824	$1,665,363,218
Total Liabilities	**$12,617,463,902**	**$12,527,781,854**	**$12,506,132,772**	**$12,505,481,758**	**$12,508,290,358**
Paid-in Capital	$2,000,000,000	$2,000,000,000	$2,000,000,000	$2,000,000,000	$2,000,000,000
Retained Earnings	$0	$2,614,868,603	$5,588,884,896	$8,918,585,414	$12,639,637,462
Earnings	$2,614,868,603	$2,974,016,293	$3,329,700,518	$3,721,052,047	$4,151,314,985
Total Capital	**$4,614,868,603**	**$7,588,884,896**	**$10,918,585,414**	**$14,639,637,462**	**$18,790,952,447**
Total Liabilities and Capital	**$17,232,332,504**	**$20,116,666,750**	**$23,424,718,186**	**$27,145,119,220**	**$31,299,242,804**
Net Worth	$4,614,868,603	$7,588,884,896	$10,918,585,414	$14,639,637,462	$18,790,952,447

Sensitivity Analysis

The sensitivity analysis below assumes that revenues are 5% higher or 5% lower than the figures projected earlier in this business plan.

Best Case Scenario (Revenue Increases by 5%)

	Year 1	Year 2	Year 3	Year 4	Year 5
Revenue	$11,000,000,000	$12,100,000,000	$13,310,000,000	$14,641,000,000	$16,105,100,000
Cost of Revenue	$4,521,639,210	$4,973,805,210	$5,471,187,810	$6,018,308,670	$6,620,141,616
Gross Margin	$6,478,360,790	$7,126,194,790	$7,838,812,190	$8,622,691,330	$9,484,958,384
Gross Margin/Revenue	58.89%	58.89%	58.89%	58.89%	58.89%
Operating Expenses	$2,716,944,558	$2,886,377,951	$3,118,930,573	$3,374,463,131	$3,655,645,252
Net Profit	$3,096,009,566	$3,510,706,062	$3,921,931,775	$4,374,355,091	$4,871,771,957
Cash Flow	$6,890,695,690	$3,948,246,236	$4,424,727,137	$4,895,092,966	$5,392,608,334
Cash Balance	$6,890,695,690	$10,838,941,927	$15,263,669,064	$20,158,762,030	$25,551,370,364
Net Profit/Revenue	28.15%	29.01%	29.47%	29.88%	30.25%

Worst Case Scenario (Revenue Decreases by 5%)

	Year 1	Year 2	Year 3	Year 4	Year 5
Revenue	$9,000,000,000	$9,900,000,000	$10,890,000,000	$11,979,000,000	$13,176,900,000
Cost of Revenue	$3,699,522,990	$4,069,476,990	$4,476,426,390	$4,924,070,730	$5,416,479,504
Gross Margin	$5,300,477,010	$5,830,523,010	$6,413,573,610	$7,054,929,270	$7,760,420,496
Gross Margin/Revenue	58.89%	58.89%	58.89%	58.89%	58.89%
Operating Expenses	$2,716,944,558	$2,886,377,951	$3,118,930,573	$3,374,463,131	$3,655,645,252
Net Profit	$2,089,507,846	$2,409,385,049	$2,710,478,982	$3,041,757,340	$3,405,914,752
Cash Flow	$5,884,193,970	$2,846,925,223	$3,213,274,344	$3,562,495,215	$3,926,751,129
Cash Balance	$5,884,193,970	$8,731,119,193	$11,944,393,538	$15,506,888,753	$19,433,639,882
Net Profit/Revenue	23.22%	24.34%	24.89%	25.39%	25.85%

Exhibits

01. Targeted Employment Area Designation Letter
02. An EB-5 Economic Analysis of the Development and Operations of PharmAGRI Capital Partners Co.
03. The Regional Center's USCIS Approval Letter
04. Preliminary Construction Schedule
05. Bid from General Contractor
06. Proposed Entity Structure
07. EIN Conf. Letter
08. Certificate of Formation
09. IBISWorld Industry Report –

Appendix I

Job Descriptions of Positions to be created

Job Descriptions of the main roles are listed below:

01. CEO

Job Description	Allocation
Define and articulate the company's vision, mission, and long-term goals.	25%
Develop and implement strategic plans to achieve sustainable growth and profitability.	20%
Generate profit and loss statements, balance sheets, and cash flow summaries.	15%
Identify emerging trends and opportunities in the development and maintain a competitive advantage.	15%
Oversee all aspects of project planning, development, and execution to ensure timely delivery and adherence to quality standards.	10%
Develop and manage budgets, ensuring prudent allocation of resources and cost control.	10%
Act as the primary representative of PharmAGRI Capital Partners Co. in interactions with investors, clients, and business partners.	5%

02. COO

Job Description	Allocation
Oversee daily operations across all departments, ensuring efficiency and productivity.	30%
Implement and monitor operational systems, processes, and best practices to improve performance.	20%
Coordinate the execution of development projects, ensuring they are delivered on time, within budget, and to the highest quality standards.	15%
Manage planning, scheduling, and execution of all projects.	10%
Collaborate with contractors, architects, and other stakeholders to resolve issues and maintain progress.	10%
Develop and manage operational budgets, ensuring cost control and resource allocation align with organizational goals.	10%
Ensure that all projects and operations comply with legal, regulatory, and environmental requirements.	5%

03. CFO

Job Description	Allocation
Develop and implement comprehensive financial strategies aligned with the company's long-term goals.	35%
Oversee financial forecasting, budgeting, and resource allocation to support development projects.	20%
Provide insights and recommendations to the CEO and leadership team on financial planning and business strategy.	15%
Identify, negotiate, and secure financing for development projects, including loans, partnerships, and investor funding.	10%
Ensure compliance with EB-5 Immigrant Program requirements (if applicable) and maintain transparency with investors.	10%
Oversee accounting operations, including accounts payable/receivable, payroll, and tax compliance.	5%
Develop risk mitigation strategies, including diversification of revenue streams and contingency planning.	5%

04. Regulatory Affairs Officer

Job Description	Allocation
Ensures all products and business processes comply with government regulations from agencies like the FDA, USDA, and EPA.	25%
Prepares and submits detailed documentation for product approval and licensing.	25%
Stays updated on changes in regulations to maintain compliance and avoid legal issues.	25%
Acts as the main point of contact for regulatory bodies during inspections or audits.	25%

05. Sales Associate

Job Description	Allocation
Address customer inquiries, concerns, or complaints, striving to resolve them in a timely and satisfactory manner.	30%
Actively engage with customers to drive sales, offering upselling and cross-selling opportunities.	20%
Understand customer needs and recommend appropriate products or services to enhance their experience.	15%
Keep informed about current promotions, product launches, and seasonal offers to maximize sales.	15%
Develop in-depth knowledge of the store's product range, including features, benefits, and pricing.	10%
Perform general store maintenance tasks such as tidying up aisles, cleaning shelves, and ensuring product labels and prices are accurate.	5%
Work closely with other team members to ensure smooth store operations and a positive work environment.	3%
Communicate effectively with the store manager and other team members to meet customer needs and achieve sales targets.	2%

06. Farm Manager

Job Description	Allocation
Directs all agricultural operations, from crop planning to harvesting and storage.	25%
Manages a team of farm workers, overseeing their schedules, training, and performance.	25%
Develops and implements sustainable farming practices to maximize yield and minimize environmental impact	25%
Manages farm budget and equipment maintenance, as well as ensures compliance with agricultural safety standards.	25%

07. Agricultural Technicians

Job Description	Allocation
Performs daily farm labor, including planting, irrigation, pest control, and harvesting crops.	25%
Operates and maintains farm machinery such as tractors, harvesters, and irrigation systems	25%
Monitors crop health, identifies signs of disease or pests, and reports issues to the Farm Manager.	25%
Assists with soil testing, data collection, and general maintenance of farm facilities.	25%

08. Agronomist

Job Description	Allocation
Specializes in soil science and crop production	25%
Conducts research and analysis to develop best practices for soil fertility, disease prevention, and crop yield optimization.	25%
Advises the Farm Manager on crop selection and rotation to ensure high-quality and high-volume production	25%
Monitors environmental conditions and recommends solutions to protect crops from drought, pests, and other stressors	25%

09. Marketing Assistant – 2 positions

Marketing Assistant	Allocation
Assist in the development and implementation of marketing campaigns, including digital advertising, email marketing, social media promotions, and print materials.	30%
Collaborate with cross-functional teams, such as sales and design, to ensure campaigns align with company goals and messaging.	20%
Track campaign performance by gathering data, analyzing results, and assisting in making recommendations for optimization and improvements.	15%
Manage and update social media platforms, including Facebook, Instagram, LinkedIn, and Twitter, ensuring regular posts and engagement.	15%
Assist in content creation for social media, such as blog posts, videos, infographics, and promotional materials.	10%
Conduct market research to identify industry trends, competitors, and customer needs to inform marketing strategies.	5%
Assist in gathering customer feedback through surveys, reviews, and interactions to improve marketing initiatives.	3%
Support administrative tasks such as organizing meetings, preparing presentations, and coordinating communications within the marketing team.	2%

010. Accountant - Positions

Accountant	Allocation
Maintain accurate financial records for all company transactions, including accounts payable, accounts receivable, payroll, and general ledger entries.	30%
Prepare monthly, quarterly, and annual financial reports, such as profit and loss statements, balance sheets, and cash flow statements, to provide management with financial insights.	20%
Ensure timely preparation and filing of all financial statements and documents in compliance with local and national regulations.	15%
Analyze budget variances and report discrepancies, helping the management team understand financial trends and improve future projections.	15%
Track and monitor cash flow to ensure there is adequate funding for day-to-day operations and future investments.	10%
Prepare and maintain documentation related to tax returns, financial audits, and other financial processes.	5%
Oversee accounts payable processes, ensuring that all bills and invoices are paid on time and accurately recorded.	5%

011. Pharmaceutical Scientist

Job Description	Allocation
Leads the extraction, purification, and analysis of active compounds from crops in a laboratory setting.	25%
Designs and executes experiments to test the efficacy and safety of potential new products	25%
Collaborates with the R&D team to optimize extraction methods and improve product purity	25%
Documents all research findings and prepares reports for regulatory submission and intellectual property protection.	25%

012. Bio-chemist

Job Description	Allocation
Investigates the chemical properties and biological processes of plant-derived compounds.	25%
Uses advanced analytical techniques to identify and characterize new molecules with therapeutic potential.	25%
Works with the pharmaceutical team to understand how compounds interact with biological systems.	25%
Contributes to the development of novel purification and formulation methods.	25%

013. Lab Technician

Job Description	Allocation
Assists scientists with a variety of laboratory tasks, including preparing samples and reagents.	25%
Maintains and calibrates lab equipment to ensure accuracy and reliability of results.	25%
Follows strict safety protocols and maintains a clean, organized work environment	25%
Records and organizes experimental data, and assists with basic data analysis under supervision.	

Appendix Ii: Year One Financials

Year 1 Revenue Forecast

	Month 1	Month 2	Month 3	Month 4	Month 5	Month 6	Month 7	Month 8	Month 9	Month 10	Month 11	Month 12
Total												
Cultivation	3 000	5 000	6 000	8 000	9 000	9 000	9 000	9 000	10 000	10 000	11 000	11 000
API Conversion	600	1 000	1 200	1 600	1 800	1 800	1 800	1 800	2 000	2 000	2 200	2 200
Dosage Formulation	960 000	1 600 000	1 920 000	2 560 000	2 880 000	2 880 000	2 880 000	2 880 000	3 200 000	3 200 000	3 520 000	3 520 000
Federal Procurement	420 000	700 000	840 000	1 120 000	1 260 000	1 260 000	1 260 000	1 260 000	1 400 000	1 400 000	1 540 000	1 540 000
Specialty Distribution	225 000	375 000	450 000	600 000	675 000	675 000	675 000	675 000	750 000	750 000	825 000	825 000
Price												
Cultivation	$5 000,00	$5 000,00	$5 000,00	$5 000,00	$5 000,00	$5 000,00	$5 000,00	$5 000,00	$5 000,00	$5 000,00	$5 000,00	$5 000,00
API Conversion	$130 000,00	$130 000,00	$130 000,00	$130 000,00	$130 000,00	$130 000,00	$130 000,00	$130 000,00	$130 000,00	$130 000,00	$130 000,00	$130 000,00
Dosage Formulation	$125,00	$125,00	$125,00	$125,00	$125,00	$125,00	$125,00	$125,00	$125,00	$125,00	$125,00	$125,00
Federal Procurement	$100,00	$100,00	$100,00	$100,00	$100,00	$100,00	$100,00	$100,00	$100,00	$100,00	$100,00	$100,00
Specialty Distribution	$200,00	$200,00	$200,00	$200,00	$200,00	$200,00	$200,00	$200,00	$200,00	$200,00	$200,00	$200,00
Revenue												
Cultivation	$15 000 000	$25 000 000	$30 000 000	$40 000 000	$45 000 000	$45 000 000	$45 000 000	$45 000 000	$50 000 000	$50 000 000	$55 000 000	$55 000 000
API Conversion	$78 000 000	$130 000 000	$156 000 000	$208 000 000	$234 000 000	$234 000 000	$234 000 000	$234 000 000	$260 000 000	$260 000 000	$286 000 000	$286 000 000
Dosage Formulation	$120 000 000	$200 000 000	$240 000 000	$320 000 000	$360 000 000	$360 000 000	$360 000 000	$360 000 000	$400 000 000	$400 000 000	$440 000 000	$440 000 000
Federal Procurement	$42 000 000	$70 000 000	$84 000 000	$112 000 000	$126 000 000	$126 000 000	$126 000 000	$126 000 000	$140 000 000	$140 000 000	$154 000 000	$154 000 000
Specialty Distribution	$45 000 000	$75 000 000	$90 000 000	$120 000 000	$135 000 000	$135 000 000	$135 000 000	$135 000 000	$150 000 000	$150 000 000	$165 000 000	$165 000 000
Total Revenue	**$300 000 000**	**$500 000 000**	**$600 000 000**	**$800 000 000**	**$900 000 000**	**$900 000 000**	**$900 000 000**	**$900 000 000**	**$1 000 000 000**	**$1 000 000 000**	**$1 100 000 000**	**$1 100 000 000**
Direct Cost												
Cultivation	$3 800,00	$3 800,00	$3 800,00	$3 800,00	$3 800,00	$3 800,00	$3 800,00	$3 800,00	$3 800,00	$3 800,00	$3 800,00	$3 800,00
API Conversion	$96 200,00	$96 200,00	$96 200,00	$96 200,00	$96 200,00	$96 200,00	$96 200,00	$96 200,00	$96 200,00	$96 200,00	$96 200,00	$96 200,00
Dosage Formulation	$32,50	$32,50	$32,50	$32,50	$32,50	$32,50	$32,50	$32,50	$32,50	$32,50	$32,50	$32,50
Federal Procurement	$26,00	$26,00	$26,00	$26,00	$26,00	$26,00	$26,00	$26,00	$26,00	$26,00	$26,00	$26,00
Specialty Distribution	$52,00	$52,00	$52,00	$52,00	$52,00	$52,00	$52,00	$52,00	$52,00	$52,00	$52,00	$52,00
Direct Cost of Revenue												
Cultivation	$11 400 000	$19 000 000	$22 800 000	$30 400 000	$34 200 000	$34 200 000	$34 200 000	$34 200 000	$38 000 000	$38 000 000	$41 800 000	$41 800 000
API Conversion	$57 720 000	$96 200 000	$115 440 000	$153 920 000	$173 160 000	$173 160 000	$173 160 000	$173 160 000	$192 400 000	$192 400 000	$211 640 000	$211 640 000
Dosage Formulation	$31 200 000	$52 000 000	$62 400 000	$83 200 000	$93 600 000	$93 600 000	$93 600 000	$93 600 000	$104 000 000	$104 000 000	$114 400 000	$114 400 000
Federal Procurement	$10 920 000	$18 200 000	$21 840 000	$29 120 000	$32 760 000	$32 760 000	$32 760 000	$32 760 000	$36 400 000	$36 400 000	$40 040 000	$40 040 000
Specialty Distribution	$11 700 000	$19 500 000	$23 400 000	$31 200 000	$35 100 000	$35 100 000	$35 100 000	$35 100 000	$39 000 000	$39 000 000	$42 900 000	$42 900 000
Subtotal Cost of Revenue	**$122 940 000**	**$204 900 000**	**$245 880 000**	**$327 840 000**	**$368 820 000**	**$368 820 000**	**$368 820 000**	**$368 820 000**	**$409 800 000**	**$409 800 000**	**$450 780 000**	**$450 780 000**

Year 1 Income Statement

	Month 1	Month 2	Month 3	Month 4	Month 5	Month 6	Month 7	Month 8	Month 9	Month 10	Month 11	Month 12
Revenue	$300 000 000	$500 000 000	$600 000 000	$800 000 000	$900 000 000	$900 000 000	$900 000 000	$900 000 000	$1 000 000 000	$1 000 000 000	$1 100 000 000	$1 100 000 000
Subtotal Cost of Revenue	$122 940 000	$204 900 000	$245 880 000	$327 840 000	$368 820 000	$368 820 000	$368 820 000	$368 820 000	$409 800 000	$409 800 000	$450 780 000	$450 780 000
Gross Receipts Tax (Delaware)	$376 425	$628 425	$754 425	$1 006 425	$1 132 425	$1 132 425	$1 132 425	$1 132 425	$1 258 425	$1 258 425	$1 384 425	$1 384 425
Total Cost of Revenue	$123 316 425	$205 528 425	$246 634 425	$328 846 425	$369 952 425	$369 952 425	$369 952 425	$369 952 425	$411 058 425	$411 058 425	$452 164 425	$452 164 425
Gross Margin	**$176 683 575**	**$294 471 575**	**$353 365 575**	**$471 153 575**	**$530 047 575**	**$530 047 575**	**$530 047 575**	**$530 047 575**	**$588 941 575**	**$588 941 575**	**$647 835 575**	**$647 835 575**
Gross Margin/Revenue	58,89%	58,89%	58,89%	58,89%	58,89%	58,89%	58,89%	58,89%	58,89%	58,89%	58,89%	58,89%
Expenses												
General & Admin Expenses	$120 000 000	$120 000 000	$120 000 000	$120 000 000	$120 000 000	$120 000 000	$120 000 000	$120 000 000	$120 000 000	$120 000 000	$120 000 000	$120 000 000
Marketing & Advertising	$41 666 667	$41 666 667	$41 666 667	$41 666 667	$41 666 667	$41 666 667	$41 666 667	$41 666 667	$41 666 667	$41 666 667	$41 666 667	$41 666 667
Legal and Professional	$35 000	$35 000	$35 000	$35 000	$35 000	$35 000	$35 000	$35 000	$35 000	$35 000	$35 000	$35 000
Licensing	$50 000	$50 000	$50 000	$50 000	$50 000	$50 000	$50 000	$50 000	$50 000	$50 000	$50 000	$50 000
Research and Development	$250 000	$250 000	$250 000	$250 000	$250 000	$250 000	$250 000	$250 000	$250 000	$250 000	$250 000	$250 000
Employees Training	$300 000	$300 000	$300 000	$300 000	$300 000	$300 000	$300 000	$300 000	$300 000	$300 000	$300 000	$300 000
Travel Related	$500 000	$500 000	$500 000	$500 000	$500 000	$500 000	$500 000	$500 000	$500 000	$500 000	$500 000	$500 000
Facility Maintenance	$16 666 667	$16 666 667	$16 666 667	$16 666 667	$16 666 667	$16 666 667	$16 666 667	$16 666 667	$16 666 667	$16 666 667	$16 666 667	$16 666 667
Startup Cost	$1 650 000	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Depreciation	$46 250 000	$46 250 000	$46 250 000	$46 250 000	$46 250 000	$46 250 000	$46 250 000	$46 250 000	$46 250 000	$46 250 000	$46 250 000	$46 250 000
Payroll Taxes	$55 796	$55 796	$55 796	$55 796	$55 796	$55 796	$55 796	$55 796	$55 796	$55 796	$55 796	$55 796
Total Personnel	$500 417	$500 417	$500 417	$500 417	$500 417	$500 417	$500 417	$500 417	$500 417	$500 417	$500 417	$500 417
Total Operating Expenses	$227 924 546	$226 274 546	$226 274 546	$226 274 546	$226 274 546	$226 274 546	$226 274 546	$226 274 546	$226 274 546	$226 274 546	$226 274 546	$226 274 546
Profit Before Interest and Taxes	($51 240 971)	$68 197 029	$127 091 029	$244 879 029	$303 773 029	$303 773 029	$303 773 029	$303 773 029	$362 667 029	$362 667 029	$421 561 029	$421 561 029
Interest on Loan Repayment	$8 125 000	$8 104 946	$8 084 810	$8 064 593	$8 044 293	$8 023 911	$8 003 447	$7 982 899	$7 962 267	$7 941 552	$7 920 753	$7 899 869
Taxes Incurred	$38 453 950	$38 453 950	$38 453 950	$38 453 950	$38 453 950	$38 453 950	$38 453 950	$38 453 950	$38 453 950	$38 453 950	$38 453 950	$38 453 950
Net Profit	($97 819 921)	$21 638 133	$80 552 268	$198 360 486	$257 274 785	$257 295 167	$257 315 632	$257 336 180	$316 250 811	$316 271 527	$375 186 326	$375 207 210
Net Profit/Revenue	-32,61%	4,33%	13,43%	24,80%	28,59%	28,59%	28,59%	28,59%	31,63%	31,63%	34,11%	34,11%

Year 1 Cash Flow

	Month 1	Month 2	Month 3	Month 4	Month 5	Month 6	Month 7	Month 8	Month 9	Month 10	Month 11	Month 12
Additional Cash Received												
Revenue	$300,000,000	$500,000,000	$600,000,000	$800,000,000	$900,000,000	$900,000,000	$900,000,000	$900,000,000	$1,000,000,000	$1,000,000,000	$1,100,000,000	$1,100,000,000
EB-5 Investors	$10,000,000,000	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Federal Loan Guarantee (USDA/DoD)	$2,000,000,000	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Private Placement	$2,000,000,000	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Subtotal Cash Received	$14,200,000,000	$466,666,667	$577,777,778	$772,222,222	$876,666,667	$884,444,444	$888,888,889	$891,666,667	$989,814,815	$991,851,852	$1,090,303,030	$1,091,919,192
Total Personnel	$500,417	$500,417	$500,417	$500,417	$500,417	$500,417	$500,417	$500,417	$500,417	$500,417	$500,417	$500,417
Bill Payments	$0	$349,419,505	$431,611,451	$472,697,315	$554,889,098	$595,974,798	$595,954,416	$595,933,951	$595,913,403	$636,998,772	$636,978,057	$678,063,257
Additional Cash Spent												
Start-up Costs	$1,650,000	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Principal Loan Repayment	$4,936,401	$4,956,455	$4,976,591	$4,996,808	$5,017,108	$5,037,490	$5,057,954	$5,078,502	$5,099,134	$5,119,849	$5,140,648	$5,161,532
Purchase Long-term Assets	$11,100,000,000	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Cash Spent	$11,107,086,818	$354,876,377	$437,088,458	$478,194,540	$560,406,622	$601,512,704	$601,512,787	$601,512,870	$601,512,954	$642,619,038	$642,619,122	$683,725,206
Net Cash Flow	$3,092,913,182	$111,790,290	$140,689,320	$294,027,682	$316,260,045	$282,931,740	$287,376,102	$290,153,796	$388,301,861	$349,232,814	$447,683,908	$408,193,986
Cash Balance	**$3,092,913,182**	**$3,204,703,473**	**$3,345,392,792**	**$3,639,420,475**	**$3,955,680,519**	**$4,238,612,259**	**$4,525,988,361**	**$4,816,142,157**	**$5,204,444,018**	**$5,553,676,833**	**$6,001,360,741**	**$6,409,554,727**

Year 1 Balance Sheet

	Month 1	Month 2	Month 3	Month 4	Month 5	Month 6	Month 7	Month 8	Month 9	Month 10	Month 11	Month 12
Current Assets												
Cash	$3,092,913,182	$3,204,703,473	$3,345,392,792	$3,639,420,475	$3,955,680,519	$4,238,612,259	$4,525,988,361	$4,816,142,157	$5,204,444,018	$5,553,676,833	$6,001,360,741	$6,409,554,727
Account Receivable	$100,000,000	$133,333,333	$155,555,556	$183,333,333	$206,666,667	$222,222,222	$233,333,333	$241,666,667	$251,851,852	$260,000,000	$269,696,970	$277,777,778
Total Current Assets	$3,192,913,182	$3,338,036,806	$3,500,948,348	$3,822,753,808	$4,162,347,186	$4,460,834,482	$4,759,321,694	$5,057,808,824	$5,456,295,870	$5,813,676,833	$6,271,057,711	$6,687,332,504
Long-term Assets												
Long-term Assets	$11,100,000,000	$11,100,000,000	$11,100,000,000	$11,100,000,000	$11,100,000,000	$11,100,000,000	$11,100,000,000	$11,100,000,000	$11,100,000,000	$11,100,000,000	$11,100,000,000	$11,100,000,000
Accumulated Depreciation	$46,250,000	$92,500,000	$138,750,000	$185,000,000	$231,250,000	$277,500,000	$323,750,000	$370,000,000	$416,250,000	$462,500,000	$508,750,000	$555,000,000
Total Long-term Assets	$11,053,750,000	$11,007,500,000	$10,961,250,000	$10,915,000,000	$10,868,750,000	$10,822,500,000	$10,776,250,000	$10,730,000,000	$10,683,750,000	$10,637,500,000	$10,591,250,000	$10,545,000,000
Total Assets	**$14,246,663,182**	**$14,345,536,806**	**$14,462,198,348**	**$14,737,753,808**	**$15,031,097,186**	**$15,283,334,482**	**$15,535,571,694**	**$15,787,808,824**	**$16,140,045,870**	**$16,451,176,833**	**$16,862,307,711**	**$17,232,332,504**
Current Liabilities												
Accounts Payable	$349,419,505	$431,611,451	$472,697,315	$554,889,098	$595,974,798	$595,954,416	$595,933,951	$595,913,403	$636,998,772	$636,978,057	$678,063,257	$678,042,374
Other Current Liabilities	$10,000,000,000	$10,000,000,000	$10,000,000,000	$10,000,000,000	$10,000,000,000	$10,000,000,000	$10,000,000,000	$10,000,000,000	$10,000,000,000	$10,000,000,000	$10,000,000,000	$10,000,000,000
Subtotal Current Liabilities	$10,349,419,505	$10,431,611,451	$10,472,697,315	$10,554,889,098	$10,595,974,798	$10,595,954,416	$10,595,933,951	$10,595,913,403	$10,636,998,772	$10,636,978,057	$10,678,063,257	$10,678,042,374
Long-term Liabilities	$1,995,063,599	$1,990,107,144	$1,985,130,553	$1,980,133,745	$1,975,116,638	$1,970,079,148	$1,965,021,194	$1,959,942,691	$1,954,843,558	$1,949,723,709	$1,944,583,060	$1,939,421,528
Total Liabilities	$12,344,483,104	$12,421,718,595	$12,457,827,868	$12,535,022,843	$12,571,091,436	$12,566,033,564	$12,560,955,145	$12,555,856,095	$12,591,842,330	$12,586,701,766	$12,622,646,318	$12,617,463,902
Paid-in Capital	$2,000,000,000	$2,000,000,000	$2,000,000,000	$2,000,000,000	$2,000,000,000	$2,000,000,000	$2,000,000,000	$2,000,000,000	$2,000,000,000	$2,000,000,000	$2,000,000,000	$2,000,000,000
Earnings	($97,819,921)	($76,181,789)	$4,370,479	$202,730,965	$460,005,750	$717,300,917	$974,616,549	$1,231,952,729	$1,548,203,540	$1,864,475,067	$2,239,661,393	$2,614,868,603
Total Capital	$1,902,180,079	$1,923,818,211	$2,004,370,479	$2,202,730,965	$2,460,005,750	$2,717,300,917	$2,974,616,549	$3,231,952,729	$3,548,203,540	$3,864,475,067	$4,239,661,393	$4,614,868,603
Total Liabilities and Capital	$14,246,663,182	$14,345,536,806	$14,462,198,348	$14,737,753,808	$15,031,097,186	$15,283,334,482	$15,535,571,694	$15,787,808,824	$16,140,045,870	$16,451,176,833	$16,862,307,711	$17,232,332,504
Net Worth	**$1,902,180,079**	**$1,923,818,211**	**$2,004,370,479**	**$2,202,730,965**	**$2,460,005,750**	**$2,717,300,917**	**$2,974,616,549**	**$3,231,952,729**	**$3,548,203,540**	**$3,864,475,067**	**$4,239,661,393**	**$4,614,868,603**